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ABSTRACT OF DISSERTATION

CROSS-TALK BETWEEN THE TUMOR SUPPRESSORS
PAR-4 AND P53
This work describes the fascinating interplay between two tumor suppressors
Prostate apoptosis response-4 (Par-4) and p53. The guardian of the genome,
p53, is frequently mutated in human cancers, and may contribute to therapeutic
resistance. However, p53 is intact and functional in normal tissues, and we
observed that specific activation of p53 in normal fibroblasts could induce
apoptosis selectively in p53-deficient cancer cells. This paracrine apoptotic effect
was executed by Par-4 secreted in response to p53 activation. Accordingly,
activation of p53 in wild-type mice, but not in p53-/- or Par-4-/- mice, caused
systemic elevation of Par-4 that induced apoptosis of p53-deficient tumor cells.
Mechanistically, p53 induced Par-4 secretion by suppressing the expression of
UACA (Uveal Auto-antigen with Coiled-coil domains and Ankyrin repeats), a
binding partner of Par-4, and thereby releasing Par-4 from sequestration by
UACA. Thus, normal cells can be empowered by p53 activation to induce Par-4
secretion for inhibition of therapy-resistant tumors.
Conversely, our studies have also revealed a definite role for Par-4 in regulating
p53 expression. The pro-apoptotic tumor suppressor Par-4 is lost, downregulated, inactivated or mutated in a number of cancers. Loss of Par-4 is
associated with therapeutic resistance and poor disease prognosis, yet the
mechanism for resistance is not clearly understood. Using genetically matched
cells, we show that Par-4 expression is required for stabilization and function of
the tumor suppressor p53, which constitutes the hub of signaling networks
controlling important cellular and organismal phenotypes. In particular, the
expression of p53 protein and its stabilization in response to genotoxic stress
were remarkably attenuated in response to Par-4 loss. Accordingly, Par-4-null or
-knockdown cells demonstrated increased resistance to apoptosis induced by
genotoxic stress. Par-4 loss resulted in elevated Mdm2 activity, which is known
to cause p53 degradation. Our findings suggest that Par-4 stabilizes p53 by
inhibiting Akt-mediated phosphorylation of Mdm2 that is known to prevent

translocation of Mdm2 into the nucleus for p53 ubiquitination and degradation.
These studies identify a novel regulatory relationship between two tumor
suppressors and may provide a better understanding of therapeutic resistance in
tumors with p53 wild type status.
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CHAPTER ONE: INTRODUCTION

In the United States, cancer is ranked second only to heart disease in terms of
the total number of deaths; and, in adults belonging to the age group 40-79
years, it is the leading cause of death (Siegel et al., 2014). According to the
report prepared by the International Agency for Research in Cancer (IARC),
cancer is the leading cause of mortality worldwide- an estimated 8.2 million
deaths was caused by cancer alone in 2012. Furthermore, cancer cases are
projected to increase by 75% globally, and reach close to 25 million over the next
two decades (World Cancer Report 2014). The global burden of cancer
continues to increase, and represents one of the most formidable public health
problems.
Extensive research in the field of cancer biology over the past few decades has
made it possible to appreciate the remarkable diversity and intricate complexities
found within this disease. It is now widely accepted that tumorigenesis involves a
multi-step process leading to an accumulation of genetic aberrations. Many adult
human tumors reflect 4-7 rate-limiting, stochastic mutation events. Often such
changes reflect a dominant gain of function in oncogenes, or a recessive loss of
function in the case of tumor suppressors, which lead to defects in cellular
regulatory processes that enable them to override cell cycle control checkpoints,
and escape apoptosis, thus tipping the balance in favor of uncontrolled growth
and proliferation. According to the model projected by Hanahan and Weinberg,
1

individual tumors will sustain as many mutation events, in as many genes, as are
necessary to acquire the six traits that today are famously known as the
“hallmarks of cancer”. These six hallmarks are: a) self-sufficiency in growth
signals; b) insensitivity to growth-inhibitory cues; c) evasion of programmed cell
death (apoptosis); d) limitless replicative potential; e) sustained angiogenesis;
and f) tissue invasion and metastasis (Hanahan and Weinberg, 2000). In
addition, in recent times, the role of a supportive microenvironment in
tumorigenesis is being increasingly appreciated. Earlier perceptions of a tumor
as an insular mass of transformed cells has given way to the concept of tumor as
an assemblage of distinct, specialized cell types and sub-types, which
collectively constitute a complex tumor microenvironment in which the dynamic
interaction between the neoplastic cells (which forms the tumor parenchyma) and
the mesenchymal compartment (which forms the tumor-associated stroma) is
believed to be increasingly important for tumor initiation, progression and
metastasis (Hanahan and Weinberg, 2011).
TUMOR SUPPRESSOR GENES
Knudson’s “two-hit theory” following his historical analysis of familial and nonfamilial retinoblastomas, the phenomenon of loss of heterozygosity (LOH), and
his mutational analysis of the Retinoblastoma gene (Rb) thereafter, laid out the
framework for the classical paradigm for tumor suppressor genes (Friend et al.,
1986; Knudson, 1971). Tumor suppressor genes have been traditionally
characterized as ‘recessive’ genes, and bi-allelic inactivation of a tumor
suppressor is considered to be essential for tumorigenesis. Thus, germline
2

mutation in a tumor suppressor gene can be cause of familial cancer syndrome
that shows an autosomal dominant pattern of inheritance. In addition, the same
tumor suppressor gene is supposed to be inactivated in a number of sporadic
cancers.
A functional classification categorizes tumor suppressors as a) gatekeepers; or
b) caretakers; or c) landscapers (Kinzler and Vogelstein, 1996, 1998).
Gatekeeper genes include all genes that have distinct function in cell cycle
regulation and in suppressing proliferation, promoting differentiation, and
inducing apoptotic cell death. Examples include APC, Rb1, PTEN, Tp53, Par-4.
Loss of function of a gatekeeper tumor suppressor is ‘rate-limiting’ for either
tumor initiation, or progression, or metastasis in multi-stage tumorigenesis.
“Caretaker” tumor suppressors function by playing pivotal roles in maintaining
genomic integrity and preventing aberrations such as aneuploidy and
microsatellite instability. Examples of this class include DNA repair genes such
as MSH2, MLH1, BRCA1, ATM etc. Disruption of a caretaker gene would lead to
increased genomic instability and higher mutation rates, thus raising the
probability of a gatekeeper being inactivated. “Landscaper” genes function by
regulating the extracellular matrix, or the expression of cell surface markers, or
by modulating the action of secreted proteins/growth factors, thus controlling the
tumor microenvironment (Kinzler and Vogelstein, 1996, 1998; Macleod, 2000).
For the purpose of this dissertation, we will focus on apoptosis (or lack thereof) in
cancer, and on the tumor suppressor genes that target apoptotic pathways as a
means to cause tumor suppression and achieve tissue homeostasis.
3

APOPTOSIS
Apoptosis is a highly organized complex process of programmed cell death that
utilizes the cellular machinery of gene transcription and translation in order to get
rid of damaged or superfluous cells. Apoptosis is characterized by distinct
morphological features such as chromatin condensation, DNA fragmentation,
membrane blebbing, preservation of organelle structure, and containment of
cellular contents within membrane-bound apoptotic bodies (Kerr et al., 1972).
Apoptotic cell death in vertebrates usually occurs via one of the two- extrinsic or
intrinsic- pathways, both of which ultimately utilize the aspartate-specific cysteine
protease (caspase)-mediated proteolytic cascade. Extrinsic (death receptorinitiated) pathway is triggered by the interaction of extracellular signals with cell
surface death receptors of the CD95 (Apo-1 or Fas)/TRAIL/TNF receptor 1
family, or Death Receptors 3, 4 and 5 (DR3, DR4, DR5), which often leads to
receptor clustering and recruitment of the adaptor protein Fas-activated Death
Domain (FADD) to the intracellular effector domain of the death receptor. FADD
proteins in turn recruit initiator procaspase 8 to form a death inducing signaling
complex (DISC).
The intrinsic (or mitochondrial) apoptotic pathway is regulated by the Bcl-2 family
of proteins, which promote or inhibit the apoptotic process by governing the
activation/inactivation of mitochondrial permeability transition pore (MPTP).
Based on functional relevance, this family is sub-divided into two groups:
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a) Anti-apoptotic group includes Bcl-2, Bcl-xL, Mcl-1, A-1, and Bcl-Wmolecules that are essential for cell survival.
b) Pro-apoptotic group is represented by proteins such as Bax and Bak,
which, among others, are essential for mitochondrial outer membrane
permeability (MOMP). Other pro-apoptotic members of this family, namely,
PUMA, Noxa, Bim, Bad and Bmf act by sequestering Bcl-2 and Bcl-xL,
and thereby inhibiting the action of these anti-apoptotic molecules.
In response to apoptotic cues such as cytotoxic stresses or developmental
signals, Bax and Bak, the pro-apoptotic members of Bcl-2 family, can homo- or
hetero-dimerize with other pro-apoptotic partners of the Bcl2 family to form pores
on the outer mitochondrial membrane, and thereby trigger the release of
apoptogenic molecules (such as cytochrome c, Smac/DIABLO) from the
mitochondria into the cytosol, leading to the formation of a procaspase-activating
adaptor protein called apoptotic protease activating factor-1 (Apaf1). Apaf1 then
recruits and activates procaspase 9. Activation of both caspases 8 and 9
unleashes the caspase cascade by activating downstream executioner caspases
(caspase-3, -6, and -7) to ultimately result in apoptosis of the cell by causing the
release of the endonuclease caspase-activated DNAse (CAD) from its inhibitor
iCAD, and by proteolytic cleavage of key cellular enzymes and proteins
(Delbridge et al., 2012; Strasser et al., 2000).

5

Apoptosis and cancer
As early as 1972, Kerr et. al. speculated that apoptosis, a highly regulated
process of “cell deletion”, was crucial to maintaining normal tissue homeostasis.
In addition, they theorized that this “cell loss factor” or apoptosis played a vital
role in counter-balancing the rapid rate of mitosis in neoplastic growth, and the
resulting equation between these two processes determined the rate of tumor
enlargement. They also proposed that apoptosis may be involved in tumor
regression following therapeutic intervention (Kerr et al., 1972). Subsequent
studies revealed a high rate of apoptosis in spontaneously regressing tumors, as
well as in tumors treated with cytotoxic anti-cancer agents (Kerr et al., 1994).
Cloning, characterization, and recognition of Bcl-2 proto-oncogene (activated by
chromosomal translocation) in B-cell follicular lymphomas consolidated the
proposition that, apart from “transforming” or “immortalizing” hyper-proliferative
phenotype that oncogenes were heretofore attributed with, oncogenes like Bcl-2
could promote tumor growth by blocking programmed cell death or apoptosis
(Lowe and Lin, 2000). Likewise, many human cancers demonstrate up- or downmodulation in the expression and/or functions of key molecules involved in the
apoptotic process at multiple layers of regulation, thus promoting incongruous
cell survival, and contributing to oncogenesis. Overexpression of Bcl-2 is
observed in non-Hodgkin’s lymphomas, small cell lung cancers, chronic
lymphocytic leukemia, neuroblastoma and prostate cancer, and this up-regulation
is also associated with a chemo-resistant phenotype (Reed, 1999; Yip and Reed,
2008). Bcl-xL is also reported to be over-expressed in multiple myeloma,
6

Kaposi’s sarcoma, colorectal adenocarcinoma, hepatocellular carcinoma, and
pancreatic cancer (Plati et al., 2011). On the other hand, loss or inactivation of
the pro-apoptotic members of the Bcl-2 family leads to defects in the apoptotic
pathway, which, in conjunction with an oncogenic mutation, is potentially
tumorigenic. For example, homozygous deletion of Bim was found in
approximately 20% of mantle cell lymphomas; and accordingly, Bim inactivation
accelerated Eμ-myc-driven lymphomagenesis in mice. Similarly, loss of PUMA in
mice also results in accelerated lymphoma development in Eμ-myc transgenic
mice, and PUMA expression is also lost from nearly 40% of Burkitt’s lymphoma.
In addition, loss of pro-apoptotic Noxa, Bax or Bmf have been shown to promote
lymphoma development in experimental mouse models, but alterations in these
genes in human cancers have not yet been reported (Delbridge et al., 2012).
This shows that deregulation of apoptosis might not exert a potent transforming
influence;

however,

it

predisposes

cells

to

survive

in

inappropriate

circumstances, and sustain other mutation(s) that can then lead to oncogenic
transformation.
Dysregulation of the extrinsic or receptor-mediated apoptotic signaling pathway is
also frequently observed in various cancers. Mutations in Fas or Fas ligand is
known to promote lympho-proliferation, and therefore constitute a predisposition
to hematopoietic malignancy in both mice and humans (Drappa et al., 1996; O'
Reilly et al., 2009; Rieux-Laucat et al., 1995). In addition, many human cancers,
for example, melanoma, hepatocellular

carcinoma, non-small cell

lung

carcinoma, endometrial, colon and prostate cancers show elevated expression of
7

caspase-inhibitory proteins known as c-FLIP (FLICE Inhibiting Proteins), which
are recruited to the DISC at the cell membrane via their Death Effector Domains
(DED), and act as Caspase-8 decoys to inhibit its activation, thereby blocking
death receptor-mediated apoptosis (Plati et al., 2011).
Another facet of caspase regulation involves the IAP (Inhibitors of Apoptosis)
family of proteins, composed of eight members, and encoded by genes BIRC1 to
BIRC-8. Among these, cellular IAP1 (c-IAP1) (BIRC2), c-IAP2 (BIRC3), XIAP
(BIRC4), and ML-IAP (BIRC7) are directly involved in apoptosis regulation
whereas the other members modulate cell survival by other means, for instance,
by cell cycle regulation or inflammation. These IAP molecules inhibit the
apoptotic process either by directly binding to the caspases and inhibiting their
activity or by virtue of their ubiquitin ligase activity (de Almagro and Vucic, 2012).
Over-expression of IAP proteins across a variety of cancers, for example, colon
cancer, breast cancer, melanomas, clear-cell renal carcinomas etc (de Almagro
and Vucic, 2012) further emphasize the fact that survival advantage acquired by
apoptosis inhibition provides an impetus to the tumorigenic process. Mutations in
caspases are not frequently encountered in cancers. Nevertheless, disruption of
Apaf-1 is associated with Noonan syndrome; caspase-10 mutations contribute to
autoimmune lympho-proliferative syndrome type II; and frameshift mutations in
caspase-5 have been observed in gastrointestinal, endometrial, and in hereditary
non-polyposis colorectal cancers (Lowe and Lin, 2000).
The process of apoptosis has evolved as a means to eliminate altered or
superfluous cells that show tumorigenic potential or otherwise threaten tissue
8

homeostasis. Conversely, transformed/neoplastic cells employ various cellular
strategies to suppress protective apoptotic response and develop significantly
increased tolerance to apoptotic stimuli such as growth factor depletion, hypoxia,
DNA damage, telomere malfunction, activation of mitogenic oncogenes, and
treatment with radiation or chemotherapy in order to acquire one of the hallmarks
of cancer- evasion of apoptosis. Some tumor suppressor genes, such as Tp53
and Par-4, play an integral role in this process of apoptosis, which constitutes a
critical aspect to tumor inhibition mediated by these tumor suppressors. We will
elaborate a little bit about these tumor suppressors, p53 and Par-4, whose crosstalk constitutes the framework of this dissertation.
TUMOR SUPPRESSOR P53
The tumor suppressor p53 appears to transcend borders of classification that
Kinzler and Vogelstein (Kinzler and Vogelstein, 1996) used to define tumor
suppressors, since p53 can be considered both as a ‘gatekeeper’ for its role in
cell cycle control and apoptosis; and a ‘caretaker’ in its role as the ‘guardian of
the genome’. However, it is interesting to note that p53, the product of the gene
Tp53, was discovered in 1979 as a 53kD protein bound by the large T-antigen
oncoprotein of the sarcoma-associated virus SV40 in transformed cells and
tumors, and was postulated to be an oncogene product linked to viral
transformation process (Lane and Crawford, 1979; Linzer and Levine, 1979).
Other observations regarding p53 around the same time seemed to support this
hypothesis. Ten years later, cloning of wild-type p53 cDNA by Finlay et. al., and
their seminal observation that wild-type p53 prevented transformation of cell
9

cultures by oncogenes began the evolution of p53 as a potential tumor
suppressor (Finlay et al., 1989).
Tumor suppression by p53
Functional studies on Tp53 performed in the decade of 1980’s led to the notion
that p53 behaved as a proto-oncogene. It was not only found complexed with
viral oncoproteins, but was observed to be over-expressed in tumor-derived and
transformed cell lines. Moreover, isolation of several cDNA clones showed that
p53 had the potential to transform cells in combination with the Ras oncogene
(Levine et al., 2004). However, the evidence for its supposed oncogenic potential
was later realized to be erroneously collected from mutant p53 cDNA clones.
Finlay et. al. demonstrated that the wild-type p53 cDNA actually blocked the
transformation process driven by the oncogenes E1A plus Ras, as well as those
initiated by mutant p53 plus Ras. They also observed that cells that were
transformed in culture selected for mutated p53, and that mutant p53 not only
lost its tumor suppressive ability, but could act in a dominant negative fashion to
inactivate wild-type p53, thus making an unambiguous case for the tumor
suppressive effects of wild-type p53 (Finlay et al., 1989). Indeed, mutations in
both alleles of Tp53 were identified in mouse tumors and in cultured human cell
lines; and in human colorectal cancers, wild-type Tp53 alleles were frequently
observed to be lost by mutations and/or deletions: all of these being definite
indications of a candidate tumor suppressor (Lane and Levine, 2010).
The ensuing upsurge of interest in p53 research continued to bring forth more
evidence in support of the tumor suppressive actions of p53. By 1992, p53 was
10

clearly established as a check-point protein involved in cell cycle arrest and in
maintaining genomic integrity following DNA damage (Lowe and Lin, 2000).
Studies with knock-out mouse models have demonstrated that mice deficient in
p53, in spite of being developmentally normal, spontaneously develop cancer
(particularly lymphomas and sarcomas) with high penetrance at a very young
age (Donehower et al., 1992; Jacks et al., 1994). P53 knock-out mice are also
more susceptible to oncogene- or carcinogen-induced tumors (Donehower and
Lozano, 2009). Additionally, transgenic mice engineered to over-express p53
were shown to be significantly resistant to cancer, thus emphasizing the tumorprotective effects of p53 (Garcia-Cao et al., 2002).
Substantive evidence from human cancers and cancer-derived cell lines has also
served to conclusively establish p53 as a bona-fide tumor suppressor. Germline
Tp53 mutations are known to cause a rare type of cancer predisposition called
the Li-Fraumeni syndrome. Li-Fraumeni patients with an inherited mutant allele of
Tp53 show an increased susceptibility to early-onset cancers of diverse types
(Levine and Oren, 2009). Approximately 50% of all sporadic human tumors show
mutations in both alleles of Tp53 gene, and more than 25,000 Tp53 mutations
have been identified so far, making it the most frequently mutated gene in all
human cancers. Moreover, both germline and somatic mutations at the Tp53
locus are usually followed by loss of heterozygosity (LOH) during tumor
progression, suggesting that a selective force inactivates wild-type p53 in the
process (Brosh and Rotter, 2009). Furthermore, p53 mutations are often
associated with advanced tumor stage and poor patient prognosis (Wallace11

Brodeur and Lowe, 1999). Approximately 75% of all p53 mutations are missense
substitutions. Mutant p53 tends to be more stable than wild-type p53 (hence the
aberrant over-expression observed in tumors). Most common p53 mutants are
known to exert tumor-promoting effects by dominant negative inactivation of
endogenous wild-type p53, in addition to oncogenic gain of function activities. It
is now known that abrogation of wild-type p53 transcriptional activity is the key
factor in the selection of such missense mutations. Not surprisingly, majority of
p53 missense mutations occurs in the DNA binding domain (DBD), thus
impacting its transactivation capacity which is crucial for its tumor suppressive
functions (Brosh and Rotter, 2009; Petitjean et al., 2007). The structure of p53;
and its central role in eliciting a transcriptional program that can control critical
cellular processes (such as cell cycle arrest, cellular senescence and apoptosis)
that bring about tumor suppression are briefly discussed below.
Structure
P53 protein, a stress-induced transcription factor, is biologically active as a
homo-tetramer comprising 4 x 393 amino acid residues; each monomer
consisting of 393 amino acids, and representing a highly modular structure of
intricate complexity. P53 contains folded DNA-binding and tetramerization
domains flanked by intrinsically disordered regions at both amino (N)- and
carboxy (C)-termini. N-terminus of p53 comprises the transcription-activation
domain (TAD) (residues 1–62), which is essential for p53 transcriptional activity.
The p53 TAD connects target gene recognition to its expression by directly
binding to the transcriptional co-activators p300/CBP and components of the
12

basic transcriptional machinery. It can be further divided into sub-domains TAD1
and TAD2, which is followed by a proline rich domain (PRD) (residues 63-94)
(Joerger and Fersht, 2010). TAD2 is shown to be essential for transcriptional
activation of a number of target apoptotic genes. In addition, the PRD is
considered necessary for apoptosis and growth suppression mediated by p53
(Harms and Chen, 2005).
Amino acid residues (94-292) in the p53 protein confer DNA-binding potential,
and therefore, constitute its “core” domain. This core domain is responsible for
recognizing and binding to its target duplex DNA in a sequence-specific manner,
and is also involved in co-repressor binding. The p53 binding-site sequence
consensus is discussed in more detail in forthcoming sections below. Nuclear
entry of p53 is regulated by a nuclear localization signaling domain (residues
316-324).

Moreover, residues 325-355 are involved in p53 tetramerization,

which is essential for its activity in vivo. Residues 356-393 of p53 form the basic
C-terminal domain (CTD) which performs important regulatory functions, and is
involved in down-modulation of DNA-binding activity of p53 core domain (Harms
and Chen, 2005; Joerger and Fersht, 2010).
P53 also interacts with a large number of protein partners, and a majority of its
interactions are mediated through its N-terminal TAD, although a good number of
partners also interact with the C-terminal domain, and only a few bind to the core
domain (Joerger and Fersht, 2010). In addition, within the N-terminal and Cterminal domains of p53 reside a multitude of amino acid residues subject to an
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array of post-translational modifications that can modulate p53 activation,
stabilization, as well as binding to its partners.
Transcriptional regulation by p53
More than three decades of research in the field of p53 has revealed that a broad
range of cellular processes are regulated by p53, and continues, to this day, to
ascribe new roles for p53 in the regulation of metabolism, autophagy, fecundity,
and various aspects of differentiation and development. The best characterized
function of p53 is that of a pivotal signaling node that translates diverse upstream
stress signals into downstream responses including, but not limited to, cell cycle
arrest, senescence, and apoptosis. As a transcriptional factor, p53 regulates the
expression of several critical molecules necessary to co-ordinate these multiple
aforementioned processes that produce anti-proliferative and anti-transformation
outcomes. Thus transcriptional regulation of its target genes by p53 is integral to
its role as a tumor suppressor.
Extensive research in the p53 field over the years has identified an estimated
several hundreds of RNA-polymerase II (RNAP II)-transcribed genes that are
directly, and thousands others that are indirectly, regulated by p53 (Beckerman
and Prives, 2010). Although p53 mRNA is constitutively expressed, basal levels
of p53 protein are kept extremely low in unstressed cells. A plethora of cellular
stresses, including but not limited to, genotoxic stresses such as radiation,
telomere erosion, nucleotide depletion; hypoxia; heat/cold shock; nutritional
starvation; mitochondrial biogenesis stress; oncogenic activation etc, can
stabilize and activate p53. Stabilization of p53 expression levels primarily occurs
14

through events that disrupt its interaction with its negative regulator Mdm2
protein, which mediates the proteasomal degradation of p53.
Once stabilized, p53 translocates into the nucleus and binds, as a tetramer,
specific DNA sequences that are designated p53 response elements (REs)
(McLure and Lee, 1998). The consensus p53-binding DNA sequence consists of
two copies of the 10-base pair motif RRRCWWGYYY (n=0-13) RRRCWWGYYY
(where R is Adenine or Guanine, W is a purine base, and Y is a pyrimidine base)
with or without a spacer region (n), which can be up to 13 bases long. C4 and G7
in each motif are considered critical for effective binding (el-Deiry et al., 1992;
Funk et al., 1992). However, an analysis of functional p53 target genes suggests
that mismatches in one or more bases in the consensus sequence do not result
in loss of binding. Non-canonical sites, such as those found in pig3 (TGYCC)n
response microsatellite element; the triplet pairs of the pentameric element at the
aqp3 locus; or the “head-to-tail” configuration of the Mdr1 site show that p53 REs
can accommodate moderate alterations in the consensus sequence (Beckerman
and Prives, 2010).
P53 REs are usually found to cluster in the non-coding areas of its target gene,
and are most commonly found in the promoter at varying distances upstream
(e.g., p21, noxa) of the transcription start site (TSS), although some might be
located closer (within 300 base pairs) of the TSS (e.g. Hdm2, Pcna). However,
these REs have also been found at diverse regions within the target gene locus;
for instance, within early intronic sequences (e.g. Puma, Pig3), and also within
exons (e.g. miR-34a). Once bound to its RE, p53 can then recruit diverse
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transcriptional co-regulators, such as histone modifying enzymes, chromatin
remodeling complexes, and components of the general transcriptional machinery
and the pre-initiation complex (PIC) to modulate RNAP II activity at the target
gene locus.
Although majority of research has focused on p53 as a transcriptional activator,
p53 can also cause repression of some of its target genes. It is yet not clear what
distinguishes an RE from being a transcriptional activator-site versus a
transcriptional-repressor site. Nonetheless, p53 is considered to cause gene
repression via the following three generally accepted mechanisms (Riley et al.,
2008):
i.

Steric interference, wherein p53 binding to its RE overlaps the binding
site of another (more powerful) trans-activating agent (e.g. Afp, Bcl-2).

ii.

P53 squelching of transcriptional activators (e.g. cyclin B1, TERT).

iii.

P53-mediated recruitment of transcriptional co-repressors, such as
histone deacetylases (HDACs) (MAP4, Hsp90AB1) (Riley et al., 2008).

Diverse cofactors that interact with, or are recruited to specific RE’s by p53, can
post-translationally modify histones, other cofactors, or p53 itself. The precise
mechanisms whereby p53 targets a select group of genes regulating a specific
pathway in response to distinct stresses are poorly understood. However, it is
now thought that combinations of cofactors and post-translational modifications
(e.g. phosphorylation, acetylation, sumoylation, neddylation etc) may serve as
distinct “barcodes” to enable the selection of specific promoters. P53 thus
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regulates a number of genes directly involved in the control of the following
cellular processes that are considered to be the mechanisms for tumor
suppression by p53: most notably cell cycle arrest, senescence, and apoptosis.
P53-mediated transactivation of p21Waf1/Cip1 is considered important for G1/S
arrest; and repression of Cdc25c, in addition to activation of 14-3-3σ can initiate
G2/M arrest (Zilfou and Lowe, 2009). P53 and its downstream effectors can
initiate a program of cellular senescence leading to a terminal state for the
replication of cells. Many studies have emphasized the importance of
senescence in the inhibition of tumor progression, and have identified a key role
for p53 and p53-regulated genes p21Waf1/Cip1 and Plasminogen Activator Inhibitor1 (PAI- 1) in this process (Vousden and Prives, 2009).
P53 and apoptosis
Incidentally, p53 was the first tumor suppressor to be linked to apoptosis, and
this aspect of p53 function constitutes one of the most extensively researched
areas in the field. Endogenous p53 has been shown to be essential for radiationinduced apoptosis in mouse thymocytes (Lowe et al., 1993b). Marked reduction
in apoptosis correlates with the occurrence of some p53 mutations in transgenic
mice, and with clonal progression in Wilm’s tumor (Lowe and Lin, 2000). Studies
using p53 knock-out mice have demonstrated that p53 plays a critical role in
apoptosis induced by a range of stimuli, including DNA damaging anti-cancer
agents, radiation, hypoxia, and mitogenic oncogenes. On the other hand, mice
expressing a p53 mutant protein that lacks the ability to induce cell cycle arrest,
but retains apoptotic potential are efficiently protected from spontaneous tumor
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development (Toledo et al., 2006). P53 regulates the promoters of numerous
genes involved in apoptosis. Upon activation, p53 transactivates various proapoptotic effectors of both intrinsic and extrinsic apoptotic pathways, including
Noxa, PUMA, Bax, PIG3, p53AIP1, Perp, CD95 and DR5 (Zilfou and Lowe,
2009). In addition, disruption of several p53 effectors, such as, Bax, Apaf-1 and
Caspase-9 can promote oncogenic transformation and tumor development in
mouse models (Lowe and Lin, 2000).
Apart from these transcription-dependent actions, p53-mediated apoptosis also
involves its transcription-independent functions. Specifically, in response to some
cell death signals, such as IR, p53 rapidly localizes to the mitochondria, where it
can induce mitochondrial outer membrane permeabilization (MOMP), thus
effecting the release of pro-apoptotic factors from the mitochondrial intermembrane space. Additionally, p53 is known to bind Bcl-2, Bcl-xL, and Bak at the
mitochondria, acting either as a direct activator of the pro-apoptotic Bax and/or
Bak, or as a derepressor. P53-regulated apoptosis effector molecule PUMA
appears to be the link between transcription-dependent and -independent
mechanisms of p53-mediated apoptosis. PUMA, which is directly up-regulated by
p53 in response to cellular stress, translocates into the mitochondria where it
interact with Bcl-xL, thus releasing p53 to activate Bax (Zilfou and Lowe, 2009).
Many more p53 target genes have been implicated in apoptosis than in other
effector functions, suggesting that its control of the apoptotic response is
complex. P53 simultaneously targets multiple death circuit pathways to coordinate an apoptotic response, and hence, no single p53-regulated molecule
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can account for all of its pro-apoptotic activity. This fact is exemplified by PUMA,
which is considered to be essential for apoptosis induction by p53, and is the
only p53 target gene whose loss produces apoptotic defect similar to that caused
by p53 loss in irradiated T lymphocytes. Yet, PUMA-null mice do not exhibit the
overt tumor-prone phenotype like their p53-null counterparts do, implying that
multiple effector functions of p53, rather than just disruption of apoptosis, must
be simultaneously inactivated to initiate tumorigenesis and that the end result of
p53 activation is context-dependent. Apoptosis can be integrated into a larger
p53 tumor suppressor network controlled by different signals, environmental
contexts, and cell type (Fridman and Lowe, 2003; Zilfou and Lowe, 2009).
Non-autonomous tumor suppression by p53
Although most of the extensive research on p53 has concentrated on the cell
autonomous role of p53 in tumor suppression, emerging evidence also points
towards non-cell autonomous tumor suppressive effects of p53. Many studies
have explored p53 status in the tumor mesenchyme, particularly in the
supporting fibroblasts that constitute the supporting stroma, and concluded that
p53 can inhibit tumorigenesis and tumor progression in a non-cell autonomous
manner. High frequencies of somatic mutations in Tp53 have been reported in
breast neoplastic epithelium and stroma (Kurose et al., 2002). There is also
evidence that tumor latency is reduced in p53-null mice relative to wild-type mice,
indicating that the presence of wild-type p53 in the host exerts an inhibitory effect
on tumor progression. In addition, reconstitution of tumors with either wild-type or
p53-/- MEFs in mice showed accelerated tumor growth in the presence of p53-null
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fibroblasts, even though the composition differed only in p53 status of fibroblasts,
the neoplastic component being identical (Kiaris et al., 2005). This reinforces the
idea that p53 loss produces a supportive stroma that is more conducive to tumor
growth. Moreover, tumor progress imposes a strong selective pressure for loss of
p53 function in cancer-associated fibroblasts (CAFs), and stromal cells frequently
show LOH at the Tp53 locus, similar to those found in primary tumors (Hill et al.,
2005; Kiaris et al., 2005; Kurose et al., 2002).
P53 and cancer therapy
Because of its control of multiple arms in the apoptotic process, the p53 pathway
can influence tumor responsiveness to therapeutic agents. Numerous cell culture
and in vivo studies have demonstrated that tumors that are wild-type for p53
undergo p53-dependent apoptosis when treated with a wide variety of
therapeutic agents, such as IR, Adriamycin, 5-Fluorouracil (5-FU), Etoposide,
Vincristine (Dudley et al., 2008; Levine, 1997; Lowe et al., 1994; Lowe et al.,
1993a; Mirzayans et al., 2013), and p53 loss/inactivation leads to resistance to
apoptosis of tumor cells in response to such agents. Additionally, cytogenetic
changes in tumor stroma including p53 mutations can compromise p53 function,
and modulate response to chemotherapy. Tumor-associated stromal cells have
been reported to show diminished p53 accumulation and decreased sensitivity to
the effects of p53-activating agents such as Etoposide and Vincristine (Dudley et
al., 2008) .
In view of such far-reaching tumor suppressive effects of p53, much scientific
effort has been channelized to reinstate p53 pathway in tumors with the help of
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gene therapy or using strategies to reactivate p53 in tumor cells, in order to
restore responsiveness to therapy and improve patient prognosis (Vousden and
Prives, 2009). Although such efforts have met with mixed results, exploring new
avenues in p53 restoration/reactivation does appear to promise therapeutic
benefit. One such approach to reactivate wild-type p53 is by inhibiting its
interaction with Mdm2, thereby increasing its half-life and leading to p53
accumulation within cells.
MURINE DOUBLE MINUTE 2 HOMOLOG (MDM2)
The expression of the tumor suppressor protein p53 is maintained at low levels
within normal unstressed cells (despite constitutive expression of its mRNA); this
tight regulation of its expression is largely attributable to Mdm2 protein. Originally
identified as a gene amplified in double minute chromosomes in mouse
fibroblasts, it is now best characterized as the negative regulator of p53 protein.
Multiple mechanisms by which Mdm2 regulates p53 expression and function
have been identified. First, Mdm2 strongly binds p53 at its N-terminal TAD1 subdomain and inhibits transcriptional activation function of p53 (Momand et al.,
1992). Second, Mdm2 is a RING-finger ubiquitin ligase with high specificity for
p53. It targets p53 for ubiquitination and thereby mediates its degradation by the
26S proteasome (Haupt et al., 1997; Honda et al., 1997; Kubbutat et al., 1997).
Third, Mdm2 contains a signal sequence that is similar to the nuclear export
signal of many viral proteins. It can, therefore, bind to p53 and promote its
nuclear export, hence making p53 inaccessible to targeted DNA for
transcriptional regulation (Chene, 2003). Furthermore, Mdm2 can also suppress
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p53 protein translation either by binding directly to p53 mRNA, or by mediating
degradation of the ribosomal protein RPL26 which has been shown to have an
obligate role for p53 translation in response to genotoxic stress (Manfredi, 2010).
On the other hand, Mdm2 gene promoter contains p53 REs, and is
transcriptionally activated by p53. Mdm2 and p53 are therefore part of an autoregulatory feedback loop.
Human Mdm2 is a protein consisting of 491 amino acids in which four distinct
regions have been defined. At the N-terminus is the binding site for p53. Central
part of the protein contains an acidic region and a zinc-finger domain, whereas
the C-terminus contains a RING finger domain. The middle region of Mdm2 is
known to interact with a number of proteins, and the C-terminus RING finger is
also a binding site for a closely related partner, Mdmx (Manfredi, 2010).
The importance of p53-Mdm2 interaction was demonstrated with homozygous
deletion of the Mdm2 gene in mice. Their embryos die very early during gestation
(blastocyst stage), but this phenotype could be rescued with additional deletion of
the Trp53 gene. This clearly indicates that, during development, regulation of p53
apoptotic activity by Mdm2 is essential (Jones et al., 1995; Montes de Oca Luna
et al., 1995). It has also been shown that Mdm2 over-expression blocks p53mediated cell cycle arrest and apoptosis (Chen et al., 1996). Many studies have
described over-expression of Mdm2 in different kinds of tumors. Increased levels
of Mdm2 can thus confer growth advantage and contribute to tumorigenesis by
inactivating the p53 pathway in cancers that do possess wild-type p53. Overexpression of Mdm2 protein can be achieved by amplification of its gene; single
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nucleotide polymorphism at position 309 (SNP309) in its gene promoter;
enhanced transcription; or increased translation (Zhao Y, 2013).
Analysis of over 3000 tumors revealed that Mdm2 gene is amplified in ~7% of
these tissues; the highest frequency of amplification being observed in soft tumor
tissues, osteosarcomas, and esophageal carcinomas (Chene, 2003). Mdm2
amplification and p53 mutations were found to be mutually exclusive. Overexpression of Mdm2 in human tumors correlates with poor clinical prognosis and
poor treatment response to current therapeutics (Zhao Y, 2013). Animal
experiments have revealed that targeted expression of Mdm2 in the mouse leads
to increased tumorigenesis. Likewise, in mouse models of cancer in which p53
inactivation is known to play a role, evidence suggests that this can also occur
through enhanced expression of Mdm2 (Manfredi, 2010).
A variety of stress signals disrupt the p53-Mdm2 interaction, thus leading to p53
accumulation/activation, and setting into motion downstream p53 effector
pathway(s). Disruption of p53-Mdm2 interaction can be achieved by two means
(Zilfou and Lowe, 2009):
a) By post-translational modifications (mainly phosphorylation) of multiple
residues in the NH2-terminus of p53 protein by various kinases including
ATM, ATR, DNA-PK, Chk1, Chk2 in response to DNA damage from IR or
chemotherapeutic agents. Such post-translational events inhibit the ability
of Mdm2 to ubiquitinate and degrade p53, thereby stabilizing its
expression.
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b) P53-Mdm2 interaction is also antagonized by negative regulation of Mdm2
mediated by p14ARF (p19ARF in mouse) in response to oncogenic
challenges, resulting in p53 protein stabilization. Notably, p14ARF binds to
Mdm2 at a site distinct from p53-Mdm2 interface, and therefore is not a
competitive inhibitor (Eischen et al., 1999; Palmero et al., 1998).
Recent evidence also suggests that mere disruption of p53-Mdm2 interaction
using chemical inhibitors, even in the absence of phosphorylation on key p53
residues, is sufficient for p53 to act as a transcriptional regulator (Thompson et
al., 2004; Vassilev et al., 2004). Likewise, ablation of Mdm2 levels using RNAi
approaches resulted in p53-dependent transcriptional activity in the absence of
either phosphorylation or acetylation on specific relevant sites (Giono and
Manfredi, 2007).
Like p53, Mdm2 protein is subject to regulation by post-translational
modifications such as phosphorylation and acetylation. Various phosphorylation
sites on Mdm2 have been identified, and based on the site and the kinase
involved, these modifications can inhibit or enhance Mdm2 activity. ATM and cAbl kinases inhibit Mdm2 activity by inducing phosphorylation of Serine 395
(S395) and Tyrosine 394 respectively. CBP/p300-mediated acetylation of Mdm2
also exerts an inhibitory effect on its activity (Kruse and Gu, 2009). Such
modifications lead to p53 accumulation and activation of p53-regulated
pathways. Conversely, phosphorylation of Mdm2 at positions S166 and S186 by
the cell survival kinase Akt/PKB not only enhances its E3 ligase activity but also
promotes its nuclear entry, and facilitates the export of p53 from the nucleus to
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the cytoplasm, leading to increased degradation of p53 and significant inhibition
of p53-mediated apoptosis (Limesand et al., 2006; Mayo and Donner, 2001).
PROSTATE APOPTOSIS RESPONSE- 4 (PAR-4)
Identification of Par-4:
The prostate apoptosis response-4 (Par-4) gene was first identified by differential
hybridization technique as an immediate early apoptotic gene induced in
response to elevated intracellular Ca2+ concentration ([Ca2+]i) in androgenindependent rat prostate cancer cell line, AT-3, treated with Ionomycin. Par-4
expression was also observed in apoptotic androgen-dependent rat ventral
prostate following castration. Furthermore, Par-4 gene induction was not
observed in liver, kidneys or other androgen receptor containing organs which do
not undergo apoptosis upon castration. This observation, combined with the fact
that Par-4 expression occurs only downstream to apoptotic signaling, and not in
other processes such as growth stimulation, necrosis, oxidative stress or growth
arrest established Par-4 as an apoptosis-specific gene (Sells et al., 1994).
Human Par-4, which was found to share significant sequence homology with its
rat counterpart, was subsequently identified in yeast-two hybrid studies as a
partner of the tumor suppressor Wilm’s tumor1 (WT1) (Johnstone et al., 1996)
and atypical Protein Kinase C (aPKC) (Diaz-Meco et al., 1996). Ubiquitous Par-4
expression has also been observed in nearly all tissues of mice, horses, pigs,
and cows. In addition, Par-4 is also known to be expressed in other vertebrates
such as fish, birds, and Xenopus (El-Guendy and Rangnekar, 2003). Constitutive
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expression of Par-4 is seen in virtually all tissues of ectodermal, mesodermal,
and endodermal origin (Boghaert et al., 1997).
Following the discovery of Par-4 and its pro-apoptotic functions, the majority of
studies revolved around its role as an intracellular protein. However, a seminal
study by Burikhanov et al. showed that Par-4 is secreted by almost all types of
cells, and is available in systemic circulation. Secretion of Par-4 was shown to
occur independently of apoptosis, and through the classical secretory pathway
involving the endoplasmic reticulum (ER) and the golgi network. Secreted Par-4
is known to retain its pro-apoptotic potential and is able to selectively target
cancer cells when applied extracellularly (Burikhanov et al., 2009). Research
over the years has established Par-4 as a cancer cell-selective pro-apoptotic
protein, and a bona fide tumor suppressor.
Structure
Human Par-4 gene has been mapped to the minus strand of chromosome 12q21
(Johnstone et al., 1998). The gene comprises seven exons and six introns, and a
total of 99.06 kb of DNA (Zhao and Rangnekar, 2008). Par-4 is known to be
evolutionarily conserved among all vertebrates (Boghaert et al., 1997). The
product of the Par-4 gene is an approximately 38 kDa protein consisting of 342
amino acids in humans; 332 amino acids in rats; and 333 amino acids in mice.
Rat and mouse Par-4 proteins exhibit a 93% amino acid homology, and rat and
human Par-4 proteins possess about 75% identical and 84% functionally similar
amino acids. Moreover, the protein domains that are presumably of high
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functional importance are 100% conserved across these three species (ElGuendy and Rangnekar, 2003).
Some of the conserved functional domains of Par-4 are: a) two putative nuclear
localization sequences (NLS) designated NLS1 (amino acid residues 20-25) and
NLS2 (a bipartite sequence comprising residues 137-153) in the N-terminal
region, b) a nuclear export sequence (NES) in the C-terminus, and c) a leucinezipper domain spanning amino acids 290-332 in the C-terminal region (ElGuendy and Rangnekar, 2003). Both NLS1 and NLS2 are conserved across the
human, mouse and rat species. However, studies using deletion mutants of Par4 have shown that only NLS2 is required for translocation of Par-4 into the
nucleus and subsequent induction of apoptosis. The leucine zipper domain at the
C-terminus of Par-4 is not required for its apoptotic function. Considering the role
of this domain in various protein-protein interactions, the leucine zipper appears
more important for the regulation of Par-4 function by partner proteins such as
WT-1, PKCζ, Akt1 etc (El-Guendy et al., 2003). Par-4 also contains in its
sequence

several

consensus

sites

for

post-translational

modifications.

Phosphorylation of Par-4 by protein kinase A- I (PKA- I) at the Threonine 155
(T155) residue is known to activate Par-4, and this step is required for Par-4
function (Gurumurthy et al., 2005). Conversely, phosphorylation of Serine 249
(S249) by the Akt1/PKB Serine/threonine (S/T) kinase has been shown to
inactivate Par-4 by subjecting it to 14-3-3-mediated sequestration in the
cytoplasm (Goswami et al., 2005). Par-4 also possesses a putative ATP/GTPbinding domain, and several consensus sites for phosphorylation by kinases
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such as protein kinase C (PKC) and casein kinase 2 (CK2), although their
functional importance remains to be investigated (Hebbar et al., 2012).
Selective for Apoptosis in Cancer Cells (SAC) Domain
Analysis of several mutants resulting from serial deletion of the full-length Par-4
protein from both the amino and carboxy termini led to the identification of a
unique core domain, spanning amino acids 137-195, that is sufficient to carry out
the apoptotic function of Par-4. It was observed that this 58-amino acid fragment
of Par-4, when over-expressed, induces apoptosis specifically in cancer cells
only, and therefore is called the ‘selective for apoptosis of cancer cells’ (SAC)
domain. The SAC domain is 100% conserved among mammals (including
rodents, humans and chimpanzee), chicken, frog and zebra fish. This segment
contains the NLS2, which facilitates its nuclear translocation, and the PKA
phosphorylation site, T155, which is responsible for its activation, but excludes
the C-terminal leucine zipper domain. It is interesting to note that the SAC
domain shows nuclear localization, and is capable of inducing apoptosis not only
in Par-4 sensitive cancer cells, such as PC3, DU145, LNCaP/IL-6, but also in the
cells that show primarily cytoplasmic localization of full-length Par-4, and are
resistant to its apoptotic actions, such as LNCaP, MCF-7 etc. However, neither
Par-4 nor the SAC domain causes apoptosis in normal cells (El-Guendy et al.,
2003).
Par-4 is a tumor suppressor
Evidence from numerous studies across a variety of human cancers, as well as
experiments in knock-out and transgenic mouse models, has validated Par-4 as
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a bona fide tumor suppressor. Pancreatic and gastric cancers frequently show a
deletion or instability in chromosome 12q21, the region where Par-4 is located
(Kimura et al., 1998; Schneider et al., 2003). It is also possible that aberrant
expression of this region contributes to Wilm’s tumorigenesis (Johnstone et al.,
1998). Par-4 is observed to be down-regulated in over 70% of renal cell
carcinoma (Cook et al., 1999); in neuroblastoma (Kogel et al., 2001); endometrial
cancer (Moreno-Bueno et al., 2007); pancreatic cancer (Ahmed et al., 2008);
breast cancer (Mendez-Lopez et al., 2010; Zapata-Benavides et al., 2009);
cholangiocarcinoma (Franchitto et al., 2010); and in high-grade glioblastoma (Liu
et al., 2014b). In prostate cancer, Par-4 is not down-regulated or mutated, but
inactivated by Akt-mediated phosphorylation and subsequent sequestration in
the cytoplasm by chaperone protein 14-3-3 (Goswami et al., 2005).
In about 32% of the endometrial carcinomas, diminished Par-4 expression was
observed to be due to promoter hypermethylation. A strong correlation was also
reported between low Par-4 levels and microsatellite instability in these tumors.
In addition, Par-4 promoter hypermethylation and silencing could also be
detected in endometrial cancer cell lines SKUT1B and AN3CA. A single base
mutation in exon 3 of the Par-4 gene, converting an Arginine residue (CGA) to a
Stop codon (TGA) thus resulting in a truncated protein, has also been identified
in endometrial cancer (Moreno-Bueno et al., 2007). In the case of breast cancer,
emerging data have implicated Par-4 down-regulation as a prognostic factor for
poor disease outcome and decreased overall survival (Mendez-Lopez et al.,
2010; Nagai et al., 2010). A recent study also identified low Par-4 expression as
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an independent predictor of reduced recurrence-free survival, and demonstrated
that down-regulation of Par-4 is necessary and sufficient to promote breast
cancer recurrence (Alvarez et al., 2013).
K-Ras mutations are the most frequent mutations in pancreatic cancer, and Par-4
is reported to be significantly down-regulated in pancreatic cancers harboring KRas mutations. Tumors with such K-ras mutations tend to be highly aggressive
and therapy-resistant, whereas tumors with higher Par-4 levels have better
prognosis (Ahmed et al., 2008). Oncogenic Ras is known to down-regulate Par-4
in a variety of cells via the MEK-ERK pathway, and this is considered to be an
important step towards Ras-induced transformation. Restoration of Par-4 levels
either by the MEK inhibition or by stable expression of ectopic Par-4 abrogates
cellular transformation (Barradas et al., 1999; Pruitt et al., 2005; Qiu et al., 1999).
Furthermore, in Ras-transformed epithelial cells, long-term decrease in Par-4
expression has been demonstrated to be achieved by MEK-dependent
hypermethylation of the Par-4 promoter (Pruitt et al., 2005). There is also
evidence that if Par-4 is reinstated in these cells by transient transfection, it will
selectively sensitize the cells expressing oncogenic Ras, but not those that lack
oncogenic Ras, to apoptosis; and this action of Par-4 is achieved by inhibition of
NF-κB-mediated transcriptional activation (Nalca et al., 1999). The tumorsuppressor function of Par-4 has also been demonstrated in hematopoietic stem
cells where it antagonizes the activation of oncogenic Ras, and disrupts BCR-Abl
signaling to produce anti-transformation outcomes (Kukoc-Zivojnov et al., 2004).
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Animal studies have demonstrated that Par-4 knockout mice are prone to
spontaneous development of tumors in various tissues, e.g. lungs, liver, urinary
bladder and endometrium, and also exhibit prostatic intraepithelial neoplasia
(PIN). The study also shows that Par-4 knockout mice are more susceptible to
chemical- or hormone-induced endometrial and prostatic lesions. Animals
homozygous for Par-4 knockout also have a significantly shorter life span
compared to heterozygous knockout or wild-type animals (Garcia-Cao et al.,
2005).
In contrast, transgenic mice over-expressing full-length Par-4 or the SAC domain
of Par-4 show remarkable protection against the growth of spontaneous or
oncogene-induced autochthonous tumors. Interestingly, when SAC transgene
was co-expressed with oncogenic SV40 antigens in mice, normal or benign
prostatic epithelial cells continued to express SAC, whereas all prostate intraepithelial neoplasia (PIN) and adenocarcinoma lesions showed down-regulation
or elimination of the SAC transgene, indicating that loss of SAC is a pre-requisite
for progression into malignant disease (Zhao et al., 2007). A similar observation
was recently made when Alvarez et. al. noted that endogenous, and even
ectopically expressed Par-4 was lost from recurrent breast tumors in their study
with mouse models (Alvarez et al., 2013). In addition, studies with transgenic
mouse models indicate that mice that express systemic Par-4/SAC protein are
resistant to the growth of non-autochthonous tumors. Importantly, transplantation
of bone marrow from cancer-resistant transgenic mice to cancer-susceptible wildtype mice conferred cancer resistance, further confirming the potent anti-tumor
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activity displayed by secretory Par-4/SAC. Moreover, intravenous injection of
recombinant Par-4 or SAC protein could effectively inhibit lung metastasis of
Lewis Lung Carcinoma (LLC 1) cells (Zhao et al., 2011). Overall, these results
reiterate the cancer cell-specific apoptotic action and tumor-suppressive role of
Par-4.
Par-4 and apoptosis
The pro-apoptotic action of Par-4 is indicated by its increased expression in
actively apoptosing cells, e.g. the granulosa cells of atretic ovarian follicles;
interdigitating web cells of the mouse embryo; involuting tadpole tail; and dying
neurons during neuronal development, wherein apoptosis induced in the neurons
serves to maintain the number of neurons in the nervous system (El-Guendy and
Rangnekar, 2003). The fact that the prostatic ductal cells do not normally express
Par-4, but when subjected to testosterone ablation by castration, these
apoptosing cells do express Par-4 further underscores the pro-apoptotic function
of Par-4 (Boghaert et al., 1997).
Studies conducted in cell culture models show that over-expression of Par-4 is
sufficient to directly induce apoptosis in most cancer cells, and this apoptotic
action of Par-4 can override cell-protective mechanisms, such as presence of
Bcl-2, Bcl-xL or absence of wild-type p53 or PTEN function. In contrast, overexpression of Par-4 does not induce apoptosis in normal or immortalized but
non-transformed cells, but only serves to

sensitize such “resistant” cells to

additional apoptotic signal(s), such as increased intracellular Calcium (Ca2+),
growth factor withdrawal, Tumor Necrosis Factor- α (TNF-α), or ultraviolet (UV),
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X-ray and gamma radiation (Chakraborty et al., 2001; El-Guendy et al., 2003;
Nalca et al., 1999). Similar to Par-4, SAC domain causes apoptosis in a wide
variety of cancer cells while leaving the normal cells unharmed (El-Guendy et al.,
2003).
The cancer cell-specific apoptotic effect of Par-4 is evident in vivo as well. A
single injection of adenoviral construct of Par-4 into solid subcutaneous tumors
produced in mice by implanting PC-3 cells resulted in a drastic reduction in tumor
volume within 3 weeks. This outcome was largely due to an increase in apoptosis
caused by Par-4 (Chakraborty et al., 2001). Similarly, in tumors generated by
xenotransplanted A375-C6 melanoma cells in SCID mice, over-expression of
Par-4 correlated with decreased tumor development, and an increase in
apoptosis

(Lucas

et

al.,

2001).

The

Par-4/SAC

transgenic

mice

are

physiologically and developmentally normal when scored in terms of fertility,
gender ratio, viability, body weight and aging characteristics, but show
remarkable resistance to the growth of spontaneous as well as induced tumors,
which further underscores the fact that Par-4 induces apoptosis specifically in
cancer cells, while normal cells are largely unaffected (Zhao et al., 2007).
A number of studies in cell culture models have described the role of Par-4 in
sensitizing different cell types to the apoptotic effects of various stimuli, such as
growth factor withdrawal, TNF- α, UV, X-ray and gamma radiation (Chakraborty
et al., 2001; Chendil et al., 2002; El-Guendy and Rangnekar, 2003; Nalca et al.,
1999). Par-4 is also considered to be an essential down-stream regulator of the
apoptotic actions of a wide variety of chemical/physical therapeutic agents such
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as Vincristine, TNF-related apoptosis inducing ligand (TRAIL), Adriamycin, and
Ionizing Radiation (IR) (Gurumurthy et al., 2005; Ranganathan and Rangnekar,
2005). Diminished expression of Par-4 has often been linked with reduced
sensitivity to apoptosis in response to treatment with therapeutic agents. Par-4 is
down-regulated in many cancers, and reduced levels or loss of Par-4 has been
shown to confer increased resistance of cancer cells to chemotherapeutic agents
such as Adriamycin, Etoposide, Vincristine, Cisplatin and 5-Fluorouracil (5-FU)
(Affar el et al., 2006; Alvarez et al., 2013; Tan et al., 2014; Wang et al., 2010). In
a recent study, extensive analysis of patient datasets revealed that breast tumors
with the poorest response to neo-adjuvant chemotherapy (represented by the
greatest amount of residual cancer burden) exhibited substantially lower
expression of Par-4 prior to therapy than tumors that showed a better response
to chemotherapy. Using clinically relevant mouse models, the same study
showed that breast cancer cells with reduced Par-4 expression could survive
apoptosis

caused

by

oncogene

inhibition

and

by

treatment

with

chemotherapeutic agents, and that this therapy-resistant population later on
emerges as recurrent tumor (Alvarez et al., 2013).
Mechanisms of apoptosis by Par-4
The apoptotic effect due to Par-4 involves either an activation of the cellular
apoptotic machinery or inhibition of the cellular pro-survival mechanisms. Par-4
induces apoptosis in cancer cells by enabling the translocation of Fas and Fas
ligand (FasL) to the plasma membrane. Fas receptor belongs to the TNFreceptor (TNFR) family of type-I transmembrane proteins that possess a
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conserved intracellular C-terminal ‘death domain’. Activation of Fas receptor, for
example by binding to FasL, triggers trimerization of the receptor, and recruits
the adapter protein FADD, thereby initiating the formation of DISC and
unleashing the caspase cascade. Therefore, in these cells, over-expression of
Par-4 is a sufficient signal for cell death (Chakraborty et al., 2001).
In parallel, Par-4 also translocates into the nucleus and inhibits NFκB-mediated
cell survival mechanisms; and this inhibition constitutes one of the essential
mechanisms of Par-4-induced apoptosis (Nalca et al., 1999). NFκB regulates a
number of pro-survival genes, including but not limited to, cell-protective genes
such as those of the Bcl-2 family, e.g. Bcl-xL, Al/Bfl1; and anti-apoptotic genes
such as X-linked inhibitor of apoptosis (XIAP) that can protect the cell from TNFinduced apoptosis (Barkett and Gilmore, 1999). Activation of Par-4 by PKAdependent phosphorylation at T155 is considered to be critical for both Fas/FasL
translocation and NF-κB inhibition (Gurumurthy et al., 2005). In other studies,
Par-4 has been shown to function in the cytoplasm, wherein it represses NFκBdependent

gene

transcription

by

inhibiting

the

TNFα-induced

nuclear

translocation of p65 (Rel A) subunit by blocking the aPKC- or IKKβ-mediated
phosphorylation of IκB, and this mechanism occurs without disrupting DNAbinding capability of the NFκB complex (Diaz-Meco et al., 1999). A novel
mechanism for Par-4-induced apoptosis in breast cancer was recently described.
In response to oncogene inhibition or treatment with chemotherapeutic agents,
Par-4 was observed to induce ZIP-kinase-dependent phosphorylation of Myosin
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Light Chain 2 (MLC2), resulting in multinucleation, and ultimately apoptosis due
to cytokinesis failure (Alvarez et al., 2013).
Apoptotic action of extracellular or secreted Par-4 is known to be mediated by
Glucose Regulated Protein 78 (GRP78), which acts as a receptor for Par-4 at the
cell surface. Par-4 is known to bind the N-terminal region of GRP78 via its SAC
domain, and this ligation results in the initiation of a robust feedback loop which
involves the trafficking of more GRP78 to cell surface in a Par-4 dependent
manner. The binding of Par-4 to GRP78 results in elevated ER stress and,
therefore, activation of the ER stress response protein PERK (PKR-like ER
kinase), which in turn leads to the activation of caspase-8 and caspase-3 through
a FADD dependent mechanism. The cancer-specific activity of secreted Par-4 is
due to differential expression of GRP78 in cancer and normal cells. GRP78 is
found almost exclusively on the surface of cancer cells, and this accounts for the
susceptibility of cancer cells to the apoptotic action of secreted Par-4 (Burikhanov
et al., 2009). Intracellularly, cancer cell specificity of Par-4 may also be due to
enhanced PKA-mediated phosphorylation of T155 residue in Par-4/SAC domain
as a result of elevated expression and/or activity of the enzyme PKA1 in cancer
cells and primary tumors compared with normal cells (Gurumurthy et al., 2005).
Project objectives
Research from our lab has shown that the tumor suppressor Par-4 is secreted,
and induces apoptosis specifically in cancer cells. Such cancer cell selectivity
exhibited by extracellular Par-4 is a much desired characteristic which can be
harnessed and exploited to conceptualize novel effective therapeutic strategies.
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The aim of this dissertation project work is to identify means to enhance Par-4
secretion and elevate its systemic levels so as to eliminate remote tumor cells
(chapter 2). Secondly, this dissertation work also investigates the mechanism(s)
related to apoptosis resistance engendered by Par-4 loss or down-regulation
using cells derived from Par-4+/+ (wild-type) or Par-4-null background (chapter 3).
Chapter 2: Par-4 mediates paracrine apoptotic effect of p53
1. To identify molecular regulator(s) of Par-4 secretion.
2. To identify mechanism by which Par-4 secretion is regulated by the said
molecular regulator.
3. To determine if small molecules can be used to modulate Par-4 secretion
and cause apoptosis of cancer cells in a paracrine manner.
Chapter 3:
1. To determine the effect of Par-4 loss on apoptosis caused by different
agents using primary fibroblasts differing only in Par-4 status.
2. To investigate the mechanisms pertaining to apoptosis resistance
engendered by Par-4 loss.
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Figure 1.1: Intrinsic and extrinsic pathways apoptotic pathways
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Figure 1.1: Intrinsic and extrinsic pathways apoptotic pathways. Apoptosis
can be initiated by activation of two distinct, albeit ultimately converging,
pathways, the “Bcl-2-regulated pathway” (left; also known as the “stress” or
“mitochondrial” or “intrinsic” pathway) and the “death receptor pathway”, also
known as the “extrinsic pathway” (right). Protein–protein interactions between
members of the Bcl-2 family govern activation of the Bcl-2-regulated pathway,
whereas binding of their cognate ligands activates the death receptors (e.g.,
FAS, TNF-R1). Intrinsic pathway leads to the activation of Caspase 9, whereas
extrinsic pathway activates Caspase 8. Cellular demolition is performed by the
effector caspases 3, 6, and 7 that act downstream of both pathways.
Figure adapted from Delbridge et. al. Cold Spring Harb Perspect Biol. 2012 Nov
1;4(11).
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Figure 1.2: Domain structure of p53

Figure 1.2: Domain structure of p53. p53 contains a natively unfolded aminoterminal transactivation domain (TAD), which can be further subdivided into the
subdomains TAD1 and TAD2, followed by a proline-rich region (PRR). The
structured DNA-binding and tetramerization domains (OD) are connected
through a ﬂexible linker region. Similarly to the TAD region, the regulatory
domain at the extreme carboxyl terminus (CTD) is also intrinsically disordered.
The vertical bars indicate “hot-spots” for relative missense-mutation frequency in
human cancer.
Figure adapted from Joerger and Fersht, Cold Spring Harb Perspect Biol. 2010
Jun;2(6).
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Figure 1.3: P53 effector pathways in mediating tumor suppression

Figure 1.3: P53 effector pathways in mediating tumor suppression. The p53
effector functions of cell cycle arrest, senescence, apoptosis, autophagy, and
metabolism regulation are co-ordinated by a number of p53 target genes. These
genes are turned on depending on the type and extent of stimulus received; cell
type; and general physiological context. These effector functions of p53 are
critical in p53-mediated tumor suppression.
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Figure 1.4: Domain structure of human Par-4

Figure 1.4: Domain structure of human Par-4. The best characterized
conserved domains of Par-4, namely, the N-terminal Nuclear Localization
Sequences 1 and 2 (NLS1 and NLS2), Selective for Apoptosis of Cancer Cells
(SAC), and the C-terminal Leucine Zipper (LZ) domains are illustrated. Activation
by PKA-mediated phosphorylation at T163 is essential for Par-4 function.
Conversely, Par-4 is inactivated by Akt-mediated phosphorylation at S230.
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Figure 1.5: Apoptosis by intracellular and extracellular Par-4

Figure 1.5: Apoptosis by intracellular and extracellular Par-4. Apoptosis
induction by Par-4 involves membrane translocation of death receptors of the
CD95 family (Fas/FasL). Ligation of Fas with FasL recruits FADD, an adapter
protein with cytoplasmic death domain, which in turn serves to recruit procaspase
8 molecules and initiate the proteolytic caspase cascade. Par-4-mediated
apoptosis also involved inhibition of NF-κB-mediated pro-survival pathways.
Extracellular Par-4 interacts with its receptor GRP78 and drives membrane
recruitment of FADD, thus initiating the extrinsic pathway for apoptosis.
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CHAPTER TWO: PAR-4 MEDIATES PARACRINE APOPTOTIC EFFECT OF P53
INTRODUCTION
Lung cancer is the leading cause of cancer deaths in both men and women in the
United States (Siegel et al., 2014). Activation of the Ras oncogene and loss of
tumor suppressor p53 are the two most commonly occurring alterations in lung
cancer (Wang et al., 2006). An intact p53 signaling pathway is believed to be
essential for growth arrest and cell death caused by diverse chemotherapeutic
agents and ionizing radiation. Conversely, loss of p53 function in the tumors may
confer therapeutic resistance, ultimately leading to death of the patients (Chen et
al., 2010; Levine, 1997; Sekido, 2001). P53 knock-out or p53-mutant mice
develop spontaneous, as well as inducible tumors (Donehower et al., 1995;
Donehower et al., 1992; Jacks et al., 1994) while p53 transgenic mice exhibit
tumor-free survival with an increased life span (Garcia-Cao et al., 2002; Matheu
et al., 2007). As up- or down-regulation of transcriptional target genes involved in
cell cycle progression or apoptosis plays an important role in the tumor
suppressor function of p53, it is not surprising that p53 is mutated within its DNA
binding domain in a large number of human cancers (Petitjean et al., 2007).
Given the role of p53- as the “guardian of the genome”- in controlling diverse
cellular processes that contribute towards preventing oncogenic transformation, it
is perhaps not surprising that a major part of p53 research has focused on its
cell-autonomous functions. However, in the recent years, with increasing interest
in the role of tumor microenvironment, we can also find a growing body of
evidence suggesting a non cell-autonomous role for p53, whereby p53 function in
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the stromal compartment can be instrumental in tumor inhibition. Kiaris et. al.
observed reduced latency in tumor development in p53-null mice relative to wildtype mice, indicating that p53 activity in the host may exert an inhibitory effect on
cancer progression (Kiaris et al., 2005). Several studies have revealed that
tumor-associated stromal cells also frequently undergo genetic alterations in the
Tp53 locus manifested by somatic mutations and loss of heterozygosity (LOH),
similar to those observed in primary tumors (Kurose et al., 2002; Moinfar et al.,
2000; Paterson et al., 2003; Wernert et al., 2001). Moreover, tumor progression
imposes a strong selective pressure for loss of p53 function in cancer-associated
fibroblasts (Addadi et al., 2010; Hill et al., 2005).
These observations support the view that p53 function in both normal and cancer
compartments of the tumor is important for suppression of tumor progression.
However, the precise mechanism by which p53 loss in normal or stromal cells
may contribute to tumor progression is not well understood. Because normal
cells in the body of the patient except in the tumor micro-environment are
expected to express wild type p53, we determined whether activation of p53
function in normal cells causes paracrine growth inhibitory effects in cancer cells.
Specifically, we asked whether p53 activation in normal cells induces the
secretion of pro-apoptotic proteins systemically and whether such proteins act to
inhibit the growth of p53-deficient tumor cells in a paracrine manner. Our findings
indicate that activation of p53 in normal cells promotes the secretion of Prostate
apoptosis response-4 (Par-4), a pro-apoptotic tumor suppressor protein
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(Burikhanov et al., 2009). Importantly, secreted Par-4 mediates a paracrine
growth-inhibitory effect by inducing apoptosis of p53-deficient cancer cells.

MATERIALS AND METHODS

Cells, plasmids, and chemical reagents
Lung cancer cells H1299, HOP92, prostate cancer cells PC-3, and primary lung
fibroblast cells HEL were from ATCC, MD. IKKβ+/+ and IKKβ-/- MEFs were
previously described (Burikhanov et al., 2013). Par-4+/+ and Par-4-/- MEFs were
derived from wild type and Par-4-null C57/B6 mice (Figure 2.5). P53+/+ and p53-/MEFs in the 3rd passage were from Tyler Jacks (MIT, MA). Nutlin-3a was from
Cayman Chemicals, and PS-1145, z-VAD-fmk and BFA were from Sigma
Chemicals. UACA constructs were described previously (Burikhanov et al.,
2013). The p53 constructs were from Wafik El-Deiry (Penn State University, PA).
Immortalized Balb/c fibroblasts (10)1, with no endogenous p53, and (10.1)Val5
cell line derived from 10(1) cells by stable transfection with the temperaturesensitive p53 allele encoding Valine at 135aa, were from Arnold Levine (Institute
for Advanced Study, NJ). The p53 mutant in (10.1)Val5 cells exhibits wild type
conformation at 32 °C, judged by p21/WAF1 induction, and mutant conformation
at 37-39 °C (Harvey and Levine, 1991; Wu and Levine, 1994).
Generation of Par-4/Pawr knock out mice
Par-4 knock out (KO) mice were generated using the C57/B6 mouse
background. As Exon 2 contains the initiating ATG codon, it was flanked by loxP
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sites. The selection marker (Neomycin, Neo) was flanked by FRT sites and
introduced into intron 2. Constitutive knock out allele was generated after in vivo
Cre-mediated recombination that resulted in deletion of Exon 2 and loss of Par-4
function, owing to removal of the initiating ATG codon. Par-4+/- mice were
intercrossed to generate Par-4-/- mice. Par-4 null mice grow normally and develop
spontaneous tumors in diverse tissues as previously reported (Moreno-Bueno et
al., 2007). MEFs isolated from the Par-4-/- mice and corresponding Par-4+/+
littermate control mice were studied for Par-4 secretion (Figure 2.5).
Co-immunoprecipitation and Western blot analysis
Protein extracted from cell lysates was filtered, pre-cleared with 25 µl (bed
volume) of protein G-Sepharose beads and immunoprecipitated with 1 µg of
respective antibodies. The eluted proteins were resolved by SDS-PAGE, and
subjected to Western blot analysis as described (Goswami et al., 2008).
Antibodies and siRNA duplexes
The polyclonal antibody for UACA was from Bethyl Laboratories. Par-4 (R332),
Col1A1 (H-197), pan-cytokeratin (C11), p53 (FL-393), p21/WAF1 (F5), and rabbit
IgG antibodies were from Santa Cruz Biotechnology, Inc. The mouse monoclonal
antibody for p53 (1C12 mAb), cleaved caspase 3 antibodies were from Cell
Signaling, and that for β-actin was from Sigma Chemical Corp. The control
siRNA and pools of siRNA for UACA were from Dharmacon and SantaCruz
Biotechnology, Inc.
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Quantitative Real Time-PCR analysis
Approximately 1x106 cells were infected with GFP control or GFP-tagged p53adenovirus for 24 hours, and total RNA was extracted using Trizol reagent.
Quantitative Real Time-PCR (qRT-PCR) was performed using SuperScript FirstStrand Synthesis System (Invitrogen) using oligo (dT) primers for RT. Brilliant II
SYBR Green Master Mix (Agilent Technologies) was used for subsequent qPCR.
Primers used for qPCR were as follows:
18S RNA
Forward primer: 5’-cgc cc tag agg tga aat tct-3’
Reverse primer: 5’-cga acc tcc gac ttt cgt tct-3’
Human UACA
Forward primer: 5’-ggc gga gaa cga taa gtt gac taa-3’
Reverse primer: 5’-cat gtt tct cgg gag cta caa ac-3’
Reverse transcriptase-PCR analysis
For

the

reverse-transcriptase

PCR

experiment

with

co-transfection,

approximately 1.5x106 IKKβ-/- cells were co-transfected with either vector, wildtype(wt) UACA, or mutant(m) UACA construct with or without p53 plasmid for 72
hours, and total RNA was extracted using RNeasy mini kit (Qiagen). Reverse
transcription was performed to synthesize cDNA with random hexamers using
SuperScript III First-Strand Synthesis System (Invitrogen), and was followed by
PCR. PCR products were then subjected to DNA gel electrophoresis. Primers
used were as follows:
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18S RNA
Forward primer: 5’- gta acc cgt tga acc cca tt -3’
Reverse primer: 5’- cca tcc aat cgg tag tag cg -3’
pCB6+ human UACA wild type or mutant constructs
Forward primer: 5’-aag agc ctc aag tcc cgc c -3’
Reverse primer: 5’- ccc ccc ttt ctg ctg ctt-3’
ChIP analysis
ChIP assays for endogenous p53 binding to the consensus binding site in UACA
were performed by treating 2x106 HEL cells with either DMSO vehicle or with
Nutlin-3a for 24 h, and 1x106 cells were used per ChIP reaction in each treatment
group. Alternatively, for ChIP analysis with ectopic p53 expression, 1x106 cells
infected with either GFP control or GFP-tagged p53-adenovirus were used per
ChIP assay.ChIP analysis was performed using the ChIP kit from Millipore
according to the instructions provided by the manufacturer. Briefly, the proteins
and DNA were cross-linked with 1% formaldehyde, lysed, and the DNA was
sheared into 200-800 bp fragments. Proteins linked to the DNA were
immunoprecipitated with appropriate antibodies (using rabbit IgG or no antibody
as control). Subsequently, immune complexes were eluted from the beads,
protein-DNA

crosslinks

were

reversed,

and

DNA

was

isolated

after

phenol/chloroform/isoamyl alcohol extraction followed by ethanol precipitation.
DNA fragments were amplified by PCR using the following primers.
UACA:
Forward primer 5’-gtc tac tcc ttg cgc gct gg-3’
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Reverse primer 5’-gcg gcg cca gac gac-3’.
p21:
Forward primer 5’-ctg gac tgg gca ctc ttg tc- 3’
Reverse primer 5’-ctc cta cca tcc cct tcc tc- 3’
GAPDH:
Forward primer 5’ – atg gtt gcc act ggg gat ct- 3’
Reverse primer 5’ – tgc caa agc cta ggg gaa ga- 3’
Apoptosis assays
Apoptotic nuclei were identified by immunocytochemical (ICC) analysis for active
caspase-3, or by 4, 6-diamidino-2-phenylindole (DAPI) staining. A total of three
independent experiments were performed; and approximately 500 cells were
scored in each experiment for apoptosis under a fluorescent microscope.
Animal experiments
Whole-blood samples and various tissues were collected from mice, 24 h after
injection via the intra-peritoneal (i.p.) route with Nutlin-3a plus PS-1145 (10mg/kg
and 5mg/kg body weight, respectively) or corn oil (100 µl) as vehicle control.
Serum was separated from the blood samples and used for testing. All animal
procedures were performed with IACUC approval.
Statistical analysis
All experiments were performed in triplicate to verify the reproducibility of the
findings. Statistical analyses were carried out with Statistical Analysis System
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software (SAS Institute, Cary, NC) and P values were calculated using the
Student t test unless otherwise mentioned.

RESULTS
Normal fibroblasts secrete Par-4 protein in a p53-dependent manner.
To examine whether p53 activation in normal cells exhibits paracrine effects in
cancer cells, we used co-cultures of mouse embryonic fibroblasts (MEFs) from
p53+/+ or p53-/- mice with p53-null H1299 and PC-3 cells and p53-mutant HOP92
cells. The cell cultures were treated with Nutlin-3a, a specific activator of p53
(Vassilev et al., 2004). Nutlin-3a induced apoptosis in p53-deficient cancer cells
that were co-cultured with p53+/+ MEFs but not with p53-/- MEFs (Figure 2.1A, left
panel). As expected, the p53-deficient cancer cells and the MEFs were resistant
to apoptosis by Nutlin-3a when cultured individually (Figure 2.1A, right panel).
Because p53 may function by partial inhibition of NF-κB activity (Dey et al.,
2007), we combined Nutlin-3a with PS-1145, a small molecule that specifically
inhibits IKKβ (Hideshima et al., 2002). By itself, PS-1145 does not induce
apoptosis of normal or lung cancer cells [Figure 1A, right panel; and (Burikhanov
et al., 2013)]. However, treatment of the co-cultures with PS-1145 induced
apoptosis in cancer cells, and the combination of Nutlin-3a plus PS-1145 highly
augmented that effect (Figure 2.1A).
To determine whether extracellular factors secreted by the MEFs in response to
Nutlin-3a and/or PS-1145 treatment contributed to apoptosis of the cancer cells,
the MEFs were treated with these small molecules, and conditioned medium
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(CM) was transferred to p53-deficient lung cancer cells or normal lung cells. The
CM from p53+/+ MEFs but not the CM from p53-/- MEFs treated with Nutlin-3a or
PS-1145 produced apoptosis of H1299 cells. Moreover, the CM from p53+/+
MEFs treated with a combination of Nutlin-3a and PS1145 exhibited an additive
apoptotic effect in H1299 cells. By contrast, the CM from MEFs treated with
Nutlin-3a and/or PS-1145 did not induce apoptosis in wild-type TP53 primary
human lung fibroblasts HEL cells (Figure 2.1B, left panel). Similarly, CM from
HEL cells treated with Nutlin-3a plus PS-1145 induced apoptosis of H1299 and
HOP92 cells, but not in HEL cells (Figure 2.1B, right panel). These findings
indicated that Nutlin-3a and PS-1145 may regulate the secretion of cancerselective pro-apoptotic factor(s) in a p53-dependent manner.
We then examined the CM for secreted proteins, especially TRAIL, maspin,
IGFBP3, and Par-4, which are known to act extracellularly and induce cancerspecific apoptosis. The CM from p53+/+ MEFs treated with Nutlin-3a or PS-1145
showed elevated levels of Par-4 protein, and combination of Nutlin-3a plus PS1145 additively increased the secretion of Par-4 (Figure 2.1C). None of the other
proteins showed elevated secretion with Nutlin-3a plus PS-1145 (data not
shown). By contrast, p53-/- MEFs accumulated Par-4 protein in the lysate, but
failed to secrete it in response to these treatments (Figure 2.1C). However,
secretion of Collagen (Col1A1) was unaffected by the treatments in p53+/+ or p53/-

MEFs, implying that p53-/- MEFs were not generally deficient in protein

secretion (Figure 2.1C, lower panel). Moreover, pre-treatment of p53+/+ cells with
pan-caspase inhibitor z-VAD-fmk did not diminish Nutlin-3a plus PS-1145-
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inducible secretion of Par-4 protein, indicating that Par-4 secretion was not a
post-apoptosis event (Figure 2.1D).
Importantly, the Par-4 antibody but not the PTEN control antibody inhibited
apoptotic activity in the CM (Figure 2.1E, left panel), implying that secreted Par-4
mediates the paracrine apoptotic action of p53. Consistent with these
observations, the CM from Par-4+/+ MEFs but not Par-4-/- MEFs treated with
Nutlin-3a plus PS-1145 induced apoptosis of p53-deficient cancer cells (Figure
2.1E, middle and right panels). Moreover, doxorubicin, which is known to activate
p53, induced Par-4 secretion from Par-4+/+ but not Par-4-/- MEFs, and the CM
collected from Par-4+/+ but not Par-4-/- MEFs induced apoptosis of p53-deficient
cancer cells (Figure 2.1F).

Together, these findings suggested that p53

regulates the secretion of Par-4 protein, which selectively induces apoptosis in
cancer cells.
p53 induces systemic expression of Par-4 in normal mice.
We examined whether p53 regulates the secretion of Par-4 in vivo. The serum of
untreated C57/B6 p53+/+ mice contained higher levels of Par-4 relative to p53-/mice (Figure 2.2A, left panel). When p53+/+, p53-/-, and Par-4-/- mice were injected
with Nutlin-3a plus PS-1145 or vehicle control, and serum samples were
collected for analysis of Par-4, we noted that relative to vehicle control, Nutlin-3a
plus PS-1145 caused a ~5-fold increase in serum levels of Par-4 protein in p53+/+
mice. By contrast, Nutlin-3a plus PS-1145 failed to elevate systemic levels of
Par-4 in p53-/- mice or Par-4-/- mice (Figure 2.2A, right panel), implying that p53
function was essential for up-regulation of Par-4 secretion in mice. Importantly,
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the serum from Nutlin-3a plus PS-1145 treated p53+/+ mice, but not p53-/- mice or
Par-4-/- mice, induced ex vivo apoptosis of cancer cell cultures but not normal cell
cultures (Figure 2.2B, upper panel). By contrast, the serum from vehicle-treated
mice failed to induce apoptosis over background levels in normal or cancer cells
(Figure 2.2B, lower panel). Moreover, pre-incubation of the serum samples
collected from Nutlin-3a plus PS-1145 treated p53+/+ mice with the Par-4 antibody
but not the PTEN control antibody, significantly inhibited the ability of the serum
to induce apoptosis of cancer cell cultures (Figure 2.2C). Together, these
findings suggest that p53 activation in normal mice induces adequate levels of
systemic Par-4 protein that is functionally effective in inducing apoptosis of
cancer cells.
P53 down-regulates the expression of UACA to induce Par-4 secretion.
As Par-4 does not contain a p53 consensus binding site in its DNA, Par-4
secretion is likely regulated by another downstream target of p53. To identify the
primary gene target of p53, we used three criteria: (1) it should encode a protein
that binds to Par-4, (2) it should be regulated by p53, and (3) it should be induced
by NF-κB activity. We recently identified UACA (uveal autoantigen with coiled-coil
domains and ankyrin repeats) as a strong binding partner of Par-4 (Burikhanov et
al., 2013). UACA was co-immunoprecipitated from normal MEF and HEL
fibroblast with Par-4 antibody, and Par-4 was reciprocally co-immunoprecipitated
with UACA antibody (Figure 2.3 A). A comparison of p53+/+ and p53-/- MEFs
indicated that UACA was lower in p53+/+ normal cells and mouse tissues relative
to p53-/- cells and mouse tissues. Nutlin-3a suppressed the expression of UACA
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in p53+/+ but not p53-/- MEFs (Figure 2.3B), implying suppression of UACA
expression by p53. Our previous studies (Burikhanov et al., 2013) have shown
that UACA is regulated by NF-κB and, as expected, UACA expression was
inhibited by PS-1145 (Figure 2.3B).
UACA levels in p53+/+ and p53-/- MEFs correlated inversely with the levels of Par4 secreted in the CM. Restoration of p53 activity in p53-/- MEFs by p53adenoviral infection or at 32oC in 10(1)/Val5 fibroblasts, which contain a
temperature-sensitive mutant of p53 (Harvey and Levine, 1991; Wu and Levine,
1994), suppressed the expression of UACA and induced secretion of Par-4
(Figure 2.3C). Moreover, knock-down of UACA using several different mouse
and human siRNA duplex pools, resulted in elevated Par-4 levels in the CM of
p53+/+ MEFs and HEL cells (Figure 2.3D). By contrast, knock down of UACA in
p53-/- MEFs did not elevate the secretion of Par-4 (Figure 2.3D), indicating that
p53 function was necessary to regulate the secretion of Par-4. Consistently,
ectopic expression of UACA inhibited the secretion of Par-4 (Figure 2.3E). UACA
binding to Par-4 was essential to prevent Par-4 secretion, and accordingly,
mutant UACA (631-1413aa), which does not bind to Par-4 (Burikhanov et al.
2013), was unable to prevent Par-4 secretion (Figure 2.3F).

UACA and p53 reciprocally regulate Par-4 secretion via the classical
pathway.
Previous studies have indicated that Par-4 is secreted via the classical ER-Golgi
pathway (Burikhanov et al., 2009), as well as via the exosomal pathway (Wang et
al., 2012). On the other hand, p53 has been shown to promote secretion of
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proteins via the exosomal pathway (Yu et al., 2006; Yu et al., 2009). To
determine whether p53 activation leads to Par-4 secretion via the classical
pathway, we used brefeldin A (BFA), which blocks the ER-Golgi pathway. BFA
inhibited the secretion of Par-4 by p53 restoration at 32oC in 10(1)/Val5
fibroblasts (Figure 2.3G, left panel). As both Nutlin-3a and PS-1145 induced the
secretion of Par-4 in a p53-dependent manner, we investigated whether Par-4
secretion following Nutlin-3a plus PS-1145 treatment occurred via the classical
pathway. Nutlin-3a plus PS-1145-inducible secretion of Par-4 from p53+/+ MEFs
was about 60% inhibited by BFA (Figure 2.3G, middle panel). These findings
imply that p53 regulates the secretion of Par-4 largely by the classical pathway.
Moreover, Par-4 secretion following UACA knock down in p53+/+ MEFs was
inhibited by BFA (Figure 2.3G, right panel). Collectively, these findings indicate
that UACA inhibition by siRNA, Nutlin-3a plus PS-1145, or p53 activation induces
Par-4 secretion via the classical pathway.

UACA is a direct target of p53.
A potential p53-binding site (el-Deiry et al., 1992) is present in the DNA
corresponding to exon 1 within the coding region of UACA (Figure 2.4A). P53
suppresses the expression of UACA RNA, as judged by qRT-PCR (Figure 2.4B).
In order to determine direct binding of p53 to its consensus binding site in UACA,
we performed chromatin immuno-precipitation (ChIP) studies in p53-deficient
cells that were infected with a GFP-p53 adenoviral expression construct. Our
results showed that ectopically expressed p53 construct was bound to the
putative p53 consensus element present in exon 1 within the UACA gene (Figure
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2.4C). We next corroborated this finding with endogenous p53. HEL cells treated
with Nutlin-3a, but not with vehicle, showed chromatin immuno-precipitation of
endogenous p53 bound to the p53-consensus motif in UACA (Figure 2.4D).
Consistently, Nutlin-3a treatment, which activates endogenous p53, suppressed
the expression of UACA in HEL cells (Figure 2.4E).
To determine whether p53 regulated UACA expression via its binding
motif in an NF-κB activity-independent manner, we performed our experiments in
IKKβ-/- MEFs, which lack NF-κB activity (Burikhanov et al., 2013; Li et al., 1999).
Nutlin-3a treatment of IKKβ-/- MEFs resulted in suppression of UACA expression
(Figure 2.4E). Moreover, ectopic p53 suppressed the expression of UACA
containing the p53-binding motif, but did not suppress the expression of mutantUACA, which contained mutations in the p53-binding sequence in IKKβ-/- MEFs
at both protein (Figure 2.4F, upper right panel), and mRNA levels (Figure 2.4F,
lower panel). Together, these findings suggest that p53 suppressed the
expression of UACA via its binding motif in an NF-κB-independent manner. Thus,
UACA is a relevant target of p53, and p53 may regulate Par-4 secretion by downregulation of UACA.
DISCUSSION
The tumor suppressor p53 is known to suppress tumor growth by intracellular
activation of growth arrest and apoptotic cell death pathways. However, p53 is
mutated in over 50% of cancers, and mutant forms of p53 may render cancer
cells resistant to both chemotherapy and radiation therapy. Lung cancer, the
leading cause of deaths in the US, is often associated with inactivating mutations
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in p53. We determined whether wild type p53 function in normal cells could be
effectively propelled to target lung cancer cells. The present study revealed that
p53 activation in normal cells induces paracrine apoptosis of p53-deficient lung
cancer and prostate cancer cells. This action of p53 is mediated by the tumor
suppressor protein Par-4. The paracrine effect of p53 activation on Par-4
secretion was bolstered by co-parallel inhibition of NF-κB activity in normal cells.
We noted that UACA binds to Par-4 and prevents it from being secreted, and
inhibition of UACA by p53 activation and/or inhibition of NF-κB activity, or several
different siRNAs, results in elevated secretion of Par-4. Importantly, Par-4
secreted by cells following co-parallel activation of p53 and inhibition of NF-κB
activity caused apoptosis in p53-deficient lung cancer cells but not normal cells.
The physiological relevance of the findings was confirmed by studies indicating
that normal cells in mice can be triggered to secrete pro-apoptotic Par-4 activity
in circulation in a p53-dependent manner. The elevated levels of Par-4 in serum
induced ex vivo apoptosis in tumor cells but not normal cells. Because our
previous studies indicated a good correlation between inhibition of lung tumors in
immuno-competent mice and induction of ex vivo apoptosis by Par-4 in the
serum of these mice [Zhao et al, 2011], the activation of p53 to trigger proapoptotic Par-4 protein secretion and elevate its systemic levels may be an
effective strategy to induce apoptosis of cancer cells that metastasize through
the circulatory route. Collectively, our findings suggest that secreted Par-4
mediates the paracrine apoptotic effects of p53, and that secretagogues of Par-4
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may therefore empower normal cells to execute paracrine tumor growth
inhibition.
Our findings indicate that Par-4 secretion following p53 activation occurs via the
classical BFA-sensitive pathway. Secretion of Par-4 via this pathway is
dependent on down-modulation of UACA, a novel functional target of p53.
Chromatin immunoprecipitation experiments confirmed that p53 directly binds to
its consensus motif in UACA. Importantly, p53 suppressed the expression of
UACA in an NF-κB-independent manner. As UACA is a principal binding partner
that sequesters Par-4 in normal cells, UACA inhibition by p53 is necessary to
release Par-4 for secretion via the classical pathway. However, normal cells
lacking p53 are deficient in Par-4 secretion despite UACA down-regulation,
implying that p53 function is critical for Par-4 secretion and is suggestive of an
additional role for p53 in triggering Par4 secretion. Several integral components
of the classical ER-Golgi-transport vesicle/membrane fusion pathway are
currently being investigated as targets for p53-dependent Par-4 secretion. Given
that previous studies have indicated that p53 regulates protein secretion via the
exosomal pathway, we tested whether Par-4 secretion is also regulated via the
exosomes. Our findings indicate that of the total Par-4 secreted by cells, <5% is
secreted via the exosomal pathway and the large majority is secreted by the
classical pathway (unpublished data).
In summary, our findings suggest that the tumor suppressor p53 regulates the
secretion of the pro-apoptotic, tumor suppressor Par-4 via the classical pathway
by suppressing UACA, and that Par-4 executes the paracrine apoptotic effects of
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p53. As systemic Par-4 inhibits the growth of lung tumors [Zhao et al, 2011], Par4 secretagogues can be exploited to activate p53 and unleash the power of
normal cells in the tumor micro- and macro-environment to elevate systemic Par4 and suppress tumor cell survival.
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Figure 2.1: P53 activation in normal cells produces paracrine apoptosis in
p53-deficient cancer cells
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Figure 2.1: P53 activation in normal cells produces paracrine apoptosis in
p53-deficient cancer cells
(A) Activation of p53 in MEFs induces apoptosis of co-cultured p53deficient cancer cells. Co-cultures of p53+/+ or p53-/- MEFs with the
indicated cancer cells, were treated with vehicle (v), Nutlin-3a (N, 10 µM)
and/or PS-1145 (P, 10 µM) for 24 h. The cells were subjected to ICC for
cytokeratins to detect epithelial cancer cells and for active caspase-3 to
determine apoptotic cells. Performed by Dr. Ravshan Burikhanov.
(B) Apoptosis of cancer cells by CM obtained from p53-activated MEFs.
P53+/+ or p53-/- MEFs were treated with vehicle (v), Nutlin-3a (N, 10 µM)
and/or PS-1145 (P, 10 µM) for 24 h, and their CM was transferred to normal
(HEL) or p53-deficient cancer (H1299) cells. Apoptotic cells were scored after
24 h by ICC for active caspase-3 (left panel). Similarly, p53+/+ or P53-/- MEFs
and HEL cells were treated with vehicle (v), Nutlin-3a (N, 10 μM) and/or PS1145 (P, 10 μM) for 24 h and the CM was transferred to various normal
(HEL) and p53-deficient cancer (H1299, HOP-92) cell lines. After 24 h, the
cells were scored for apoptosis (right panel).
(C) Co-parallel activation of p53 and inhibition of NF-κB activity additively
increases Par-4 secretion in fibroblasts. MEFs were treated with vehicle
(v), Nutlin-3a (N) and/or PS-1145 (P) for 24 h, and their CM, as well as
whole-cell lysates were subjected to Western blot analysis for Par-4. β-actin
was used to normalize loading of lysate. Coomassie blue-stained albumin in
the serum was used to normalize loading of CM. Par-4 secretion, but not
Col1A1 secretion, was dependent on the p53 status of the cells. Fold change
in secreted Par-4 is shown.
(D) Par-4 secretion in response to p53 activation does not require
apoptosis of the normal cells. P53+/+ or P53-/- MEFs were treated with zVAD-fmk (2 µM) and with Nutlin-3a (N, 10 μM) plus PS-1145 (P, 10 μM) or
vehicle (v) for 24 h. The CM was examined for Par-4 levels by Western blot
analysis.
(E) Par-4 secretion is critical for the paracrine effect resulting from
simultaneous p53-activation and NF-κB-inhibition. The CM from p53+/+
cells treated with Nutlin-3a + PS-1145 was incubated with polyclonal
antibody for Par-4 or PTEN control, and then added to H1299 cells.
Apoptosis of H1299 cells was scored after 24 h by ICC for active caspase 3
(left panel). Par-4+/+ and Par-4-/- MEFs were treated with Nutlin-3a + PS-1145
(N+P) or vehicle, then the CM was applied to the indicated cell lines, and
apoptotic cells were scored by ICC for active caspase-3 (middle panel).
Expression of Par-4 in CM was verified on Western blots (right panel).
Performed by Dr. Ravshan Burikhanov.
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(F) Doxorubicin induces paracrine apoptosis of cancer cells by Par-4

secretion. PC-3 cells were treated with 100 nM doxorubicin (Dox) or vehicle
for 24 h and scored for apoptosis by ICC for active caspase-3. Note 100 nM
Dox does not directly induce apoptosis in PC-3 cells (middle panel). Par-4+/+
or Par-4-/- MEFs were treated with 100 nM doxorubicin (Dox) or vehicle for 24
h and the CM from these cells was transferred to PC-3 cells; after 24 h the
PC-3 cells were scored for apoptosis (left panel). Elevation of Par-4 in the
CM of doxorubicin (Dox)- or vehicle (v)-treated Par-4+/+ or Par-4-/- MEFs was
confirmed by Western blot analysis (right panel). Right panel performed by
Dr. Ravshan Burikhanov.
(A, B) Asterisk (*) indicates statistical significance (P < 0.001) by the Student t
test. (**) indicates that N+P is significantly (P < 0.001) more effective than
individual treatments among different cell lines based on two-way ANOVA
followed by Bonferroni correction.
(E, F) (**) indicates that the indicated treatments are significantly (P < 0.001)
more effective than their respective control groups based on two-way
ANOVA followed by Bonferroni correction.
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Figure 2.2: Activation of p53 in mice induces systemic expression of Par-4
pro-apoptotic activity
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Figure 2.2: Activation of p53 in mice induces systemic expression of Par-4
pro-apoptotic activity.
(A) P53 function is essential for induction of systemic Par-4 in mice. Serum
samples from p53+/+ mice (4 µl per lane) and p53-/- mice (8 µl per lane) (left
panel); and also from p53+/+, p53-/-, and Par-4-/- mice (right panel) injected via
i.p. route with either vehicle (v) or with Nutlin-3a + PS-1145 (N+P) were
examined for Par-4 expression by Western blot analysis using serum
albumin to normalize loading. Data are representative of 4 mice per
treatment. Performed by Dr. Ravshan Burikhanov.
(B) Serum from Nutlin-3a plus PS-1145-treated p53+/+ mice induces ex vivo
apoptosis of cancer cells. Serum samples collected from p53+/+, p53-/-, and
Par-4-/- mice injected i.p. with either vehicle (lower panel) or with Nutlin-3a +
PS-1145 (N+P) (upper panel) was applied at a final concentration of 10% to
the indicated normal or cancer cell lines. The cells were scored for apoptosis
after 24 h. Fetal bovine serum (FBS, 10%) was used as an additional control.
Performed by Dr. Ravshan Burikhanov.
(C) Secreted Par-4 is essential for the paracrine effect of p53 activation.
Serum samples collected from p53+/+ mice treated with vehicle or Nutlin-3a +
PS-1145 (N+P) were pre-incubated with Par-4 antibody, control PTEN
antibody or no antibody (Ab), and then applied on lung cancer cells. After 24
hours of treatment, the cells were scored for apoptosis. Performed by Dr.
Ravshan Burikhanov.
(B) Asterisk (**) indicates there is a significant (P < 0.001) increase in apoptosis
of cancer cells with serum obtained from p53+/+ mice treated with N+P,
based on two-way ANOVA followed by Tukey’s test.
(C) Asterisk (*) indicates statistically significant (P< 0.001) increase in apoptosis
of cancer cells with serum obtained from wild-type mice treated with N+P,
and (**) indicates significant (P< 0.001) reduction in this effect when Par-4
antibody is used. The statistical analysis was performed using two-way
ANOVA followed by Tukey’s test.
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Figure 2.3: P53 stimulates Par-4 secretion by suppressing the expression
of UACA
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Figure 2.3: P53 stimulates Par-4 secretion by suppressing the expression
of UACA.
(A) UACA binds to Par-4 in fibroblasts. Whole-cell lysates of human lung
fibroblasts HEL and p53+/+ MEFs were subjected to co-immunoprecipitation
with Par-4, UACA, or p65/NF-κB (control) antibody. The immunoprecipitates
and input lysates were examined by Western blot analysis to anallyze
binding interaction between Par-4 and UACA in fibroblasts.
(B) P53 down-regulates UACA. Whole-cell lysates from p53+/+ and p53-/- MEFs
that were either untreated or treated with vehicle (v), Nutlin-3a (N, 10µM), or
PS-1145 (P, 10 µM) for 24 hours (left 3 panels) ; or whole-tissue lysates of
highly vascular organs obtained from p53+/+ and p53-/- mice (right 3 panels),
were examined for UACA by Western blot analysis. Right panel performed
by Dr. Ravshan Burikhanov.
(C) Restoration of p53 activity inhibits UACA expression and promotes
Par-4 secretion. CM or whole-cell lysates from p53+/+ and p53-/- MEFs were
subjected to Western blot analysis for UACA or Par-4 expression. Results
indicate an inverse relation between UACA expression and Par-4 secretion
(left panel). P53-/- MEFs were infected with GFP-tagged p53- or GFPproducing adenoviral constructs (middle panel). Also, the mouse fibroblasts
10(1), which do not express any p53, and 10(1) derived Val5 cells, which are
engineered to stably over-express wild-type p53 at 32 °C or mutant p53 at
37 °C, were grown at 37oC or shifted to 32oC to activate p53 (right panel).
Expression of the indicated proteins in the CM or whole-cell lysate was
examined by Western blot analysis. Middle panel performed by Dr. Ravshan
Burikhanov.
(D) UACA inhibits Par-4 secretion. UACA expression was knocked down in
mouse (p53+/+ MEF) and human (HEL) cells with distinct siRNA pools from
two different sources- Dharmacon (D), and SantaCruz Biotechnology, Inc.
(SC), and the CM, as well as the whole cell lysates, were subjected to
Western blot analysis. C, control (scrambled) siRNA. Performed by Dr.
Ravshan Burikhanov.
(E) Ectopic expression of UACA inhibits the secretion of Par-4. MEFs from
Par-4-/- mice were co-transfected with Par-4 expression construct plus vector
control, Par-4 and UACA expression construct (1:1 ratio), or with vector
control. Transfected populations were selected, confirmed for stable
expression of Par-4 and UACA using whole-cell lysates, and then secretion
of Par-4 in the CM was examined by Western blot analysis. Performed by Dr.
Ravshan Burikhanov.
(F) UACA binding to Par-4 is essential in order to prevent Par-4 secretion.
Par-4+/+ MEFs were transfected with expression constructs for Red
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Fluorescent Protein (RFP; vector), RFP-tagged UACA, or RFP-tagged UACA
deletion mutants, 1-630 (which binds to Par-4) or 631-1413 (which does not
bind to Par-4) (Burikhanov et al., 2013). Transfected populations were
selected, confirmed for stable expression of UACA or UACA-mutants using
whole-cell lysates, and secretion of Par-4 in their CM was determined by
Western blot analysis. Diagrammatical representations of full-length UACA
and its deletion mutants are shown (right panel). Performed by Dr. Ravshan
Burikhanov.
(G) P53 activation and UACA inhibition promotes secretion by a BFAsensitive pathway. 10(1)/Val5 fibroblasts grown at 32oC were treated with
BFA (1 µg/ml) or vehicle (v) for 3 h (left panel). UACA expression was
knocked down in MEFs (p53+/+) with Nutlin-3a plus PS-1145 (N+P; 10 µM
each) or vehicle (v) control (middle panel), or with an siRNA pool (from
Dharmacon) (right panel), and then the cells were further placed in the
presence of BFA or vehicle (v) for 3 h. The CM, as well as the whole-cell
lysates, were subjected to Western blot analysis. Right panel performed by
Dr. Ravshan Burikhanov.
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Figure 2.4: P53 directly binds to UACA and inhibits its expression
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Figure 2.4: P53 directly binds to UACA and inhibits its expression.
(A)

Comparison of the p53 response elements in UACA and p21, and
location of wild type p53 binding motif and mutations introduced
in UACA. The p53 binding site consensus DNA motif is shown along
with the p53-binding motifs in UACA and p21. The indicated mutations
were introduced at C4, G7, C14 and G17 into the p53-binding motif of
UACA. P21 has two p53-binding motifs (#1 and #2). The base pairs in
the p53-binding motif of p21 that deviate from the p53 consensus
binding motif are underlined. Mutant-UACA with the altered p53binding site was generated by PCR using mutant-UACA primers and
wild type UACA DNA as template. Fidelity of the constructs was
confirmed by Retrogen Inc., CA.

(B)

P53 inhibits the expression of UACA RNA. Cells were infected with
either control GFP-producing adenovirus or GFP-tagged p53producing adenovirus for 24 h. Total RNA was isolated from each of
the samples and subjected to qRT-PCR (upper panel) or subjected to
Western blot analysis (lower panel). Performed by Dr. Shirley Qiu.

(C)

P53 binds to its consensus binding motif in UACA. A putative p53
binding motif (5’-GGAC4GTG7CCCGGCC14CCG17CGTC-3’; where C4
and G7 have been previously shown to be critical) is present in the
coding region of UACA. P53-deficient cells were infected with GFPtagged p53- or GFP-producing adenovirus and subjected to ChIP
analysis with p53 antibody (Ab) or control rabbit Ab, and
immunoprecipitated DNA fragments were analyzed by PCR with
primers flanking the p53 binding site.

(D)

Endogenous p53 binds to its consensus binding motif in UACA.
HEL cells were treated with Nutlin-3a (N) or vehicle (v) for 24 h and
subjected to ChIP analysis with p53 antibody (Ab) or control rabbit IgG
Ab, and immunoprecipitated DNA fragments were analyzed by PCR
with primers flanking the p53-binding site in UACA. Primers flanking
the p53-binding motif #1 in p21 (Figure 2.4A) or for GAPDH (which
does not contain a p53-binding site), were used as positive or negative
control, respectively. Input samples for each set of primers are shown.

(E)

Nutlin-3a causes inhibition of endogenous UACA expression in
an NF-κB independent manner. IKKβ-/- MEFs or IKKβ+/+ MEFs and
HEL cells, as controls, were treated with Nutlin-3a or vehicle for 24 h,
and whole-cell lysates were subjected to Western blot analysis for
UACA, p53 or actin.

(F)

P53 regulates UACA expression via its binding motif in an NF-κB
activity-independent manner. IKKβ-/- MEFs or IKKβ+/+ MEFs, as
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controls, were co-transfected with the indicated expression constructs.
Whole-cell lysates were subjected to Western blot analysis for UACA,
p53 or actin (top panels) or RNA was prepared from the cells and
subjected to reverse transcriptase PCR for UACA and 18S rRNA
(bottom panel). Wild type (wt) UACA contained wild type p53-binding
motif 5’-GGAC4GTG7CCCGGCC14C CG17CGTC-3’, and mutant (m)
UACA contained mutations 5’-GGAT4GTA7 CCCGGCG14CCA17CGTC3’ in the p53 binding motifs.
Top right panel performed by Dr. Ravshan Burikhanov, and bottom
panel performed by Nikhil Hebbar.
(B) Asterisk (*) indicates statistical significance (P< 0.001) by the Student t test.
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Fig 2.5: Generation of PAWR knock-out mice

Fig 2.5: Generation of PAWR knock-out mice: Diagrammatical illustration of
the targeting cassette used in the generation of PAWR knock-out mice, as
described in Materials and Methods section.
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CHAPTER 3: PAR-4 REGULATES P53 STABILITY
INTRODUCTION
Since the discovery of Par-4 in 1994, research in this field has primarily revolved
around the apoptotic function of Par-4. The apoptotic nature of Par-4 is
exemplified by its elevated expression in cells undergoing active apoptosis, for
example, granulosa cells of atretic ovarian follicles, interdigitating web cells of the
mouse embryo, involuting tadpole tails, and dying neurons during neuronal
development (El-Guendy and Rangnekar, 2003). Par-4 is reported to be an
essential downstream regulator of the apoptotic action of various physical and
chemical agents, such as TRAIL, Vincristine, Adriamycin, and Ionizing Radiation
(IR) (Gurumurthy et al., 2005; Ranganathan and Rangnekar, 2005). In addition,
several studies in cell culture models have emphasized the role of Par-4 in
sensitizing different cell types to a wide array of apoptotic stimuli, namely, growth
factor withdrawal; tumor necrosis factor-α (TNF- α); ultraviolet (UV), X-ray and
gamma radiation (Chakraborty et al., 2001; Chendil et al., 2002; El-Guendy and
Rangnekar, 2003; Nalca et al., 1999); as well as to chemotherapeutic agents
such as Docetaxel (Pereira et al., 2013) and 5-Fluorouracil (5-FU) (Wang et al.,
2010). Induction of cancer cell-specific apoptosis by Par-4 in involves
concomitant activation of the pro-death pathway mediated by Fas/Fas ligand
(Fas/FasL) and inhibition of pro-survival pathway mediated by Nuclear Factorkappa B (NF-κB) (Chakraborty et al., 2001). In addition, some reports have cited
Par-4-mediated repression of the Bcl-2 gene as a factor contributing to
apoptosis-sensitizing action of Par-4 (Chendil et al., 2002; Wang et al., 2010).
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A predominant observation across a broad spectrum of human cancer cells
denotes that cells that have down-modulated or lost the expression of Par-4
exhibit increased resistance to apoptosis due to therapeutic agents such as
Etoposide, Vincristine, Adriamycin, and Cisplatin (Affar el et al., 2006; Alvarez et
al., 2013; Tan et al., 2014). Low Par-4 expression was also identified as the
reason for diminished sensitivity of oncogene-driven breast cancer cells to
apoptosis following oncogene inhibition (Alvarez et al., 2013). Furthermore,
inactivation of Par-4 by Akt-mediated phosphorylation and subsequent
cytoplasmic retention was also noted to inhibit apoptosis in prostate cancer
(Goswami et al., 2005). Consistent with these observations, reduced Par-4
expression is known to correlate with decreased overall survival in pancreatic
(Ahmed et al., 2008) and breast cancers (Mendez-Lopez et al., 2010; Nagai et
al., 2010), and glioblastomas (Liu et al., 2014b), as well as reduced recurrencefree survival in breast cancers (Alvarez et al., 2013).
Despite such glaring instances which place Par-4 right at the center of apoptosis
evasion, therapy resistance, and poor disease prognosis, not enough is
understood about the mechanism(s) that contribute to the apoptotic pathway
mediated by Par-4 in response to various physical and chemical stimuli. High
resistance to apoptosis shown by Par-4-null cancer cells is reminiscent of
therapeutic resistance conferred by p53 loss (or mutation/inactivation) to UV
(Barley et al., 1998; Mirzayans et al., 2013), IR (Lowe et al., 1993b; Mirzayans et
al., 2013), and to chemotherapeutic agents such as Adriamycin, 5-FU (Lowe et
al., 1993a), as well as to Etoposide and Vincristine (Dudley et al., 2008). All of
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such studies have been performed in cancer cells, which by dint of genomic
instability, might harbor many more genetic changes than just Par-4 loss or
down-regulation. One study (Affar el et al., 2006) has utilized primary cells, but
the MEFs used do not represent true Par-4 loss because they express a leucine
zipper deletion mutant of Par-4, which still contains the potent SAC domain. In
this study, for the first time, we study the functional relevance of Par-4 loss using
MEFs prepared from Par-4 knock-out embryos. We demonstrate that loss of Par4 results in a significant reduction in p53 expression, as well as function. In
addition, our findings indicate that attenuation of p53 stabilization renders the
Par-4-null cells resistant to apoptosis in response to genotoxic stresses such as
treatment with 5-FU or IR. Mechanistically, Par-4 appears to stabilize p53 by
preventing Akt-mediated phosphorylation of Mdm2, thereby inhibiting stabilization
and nuclear translocation of Mdm2.
MATERIALS AND METHODS
Cell lines and generation of Par-4+/+ and Par-4-/- MEFs
A549 and HOP92 lung cancer cells were from ATCC; and were cultured in
RPMI+10% FBS. Cells expressing constitutively active Akt were kindly provided
by Dr. Morris Birnbaum (University of Pennsylvania).
Par-4-/- and Par-4+/+ MEFs were generated from C57BL/6 Par-4 knock-out mice
and from their wild-type littermates (Burikhanov et al., 2014a), and were grown in
DMEM supplemented with 10% Fetal Bovine Serum (FBS). Briefly, 14.5 days old
embryos were isolated from female uteri; heads were severed and used for
genotyping. The embryos were cleaned to remove unwanted tissues; each
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embryo was placed in a separate petri dish, and aseptically minced into fine
fragments with a clean razor blade. The resulting pulp was transferred into a tube
containing trypsin, pipetted to disintegrate tissue clumps, and incubated for
approximately 10 minutes. This process was repeated until a satisfactory cell
suspension was obtained. The cell suspension was then transferred to a tube
containing pre-warmed media, centrifuged, and plated in DMEM supplemented
with 15% FBS, non-essential amino acids (NEAA), glutamine, and sodium
pyruvate.
Generation of stable cell lines
pLKO.1 lentiviral vectors expressing control short hairpin (sh)RNA or shRNAs
targeting Par-4 were gift from Dr. Zhang. pLKO.1 lentiviruses were packaged by
co-transfecting the pMD2.G (VSVG) envelope plasmid and Gag, Pol expressing
psPAX2 packaging plasmid (both from Addgene) into HEK-293T cells. Cells were
cultured for 48 hours after transfection and the lentiviral particles collected from
the supernatants were used to transduce A549 and HOP92 cell with or without
concentration using Lenti-X Concentrator (Clontech). Cells were subsequently
selected with puromycin and gene silencing efficiency was analyzed by
immunoblotting for the respective proteins.
Plasmid constructs and reagents
Luciferase construct containing wild-type p53 consensus binding sites (PG13)
was purchased from Addgene. Par-4 shRNA construct in pLKO.1 vector, and
Adenoviral p53 constructs were kindly provided by Dr. Zhang and Dr. Wafik elDeiry (Penn State University), respectively. Par-4 adenoviral constructs have
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been described previously (Chakraborty et al., 2001). Nutlin-3a was purchased
from Cayman Chemicals. Cycloheximide and 5-FU were from Sigma.
Western blotting and antibodies
Cell lysates or tissue extracts were subjected to gel electrophoresis by SDSPAGE followed by western blotting with appropriate antibodies. Par-4 (R-332),
Akt-1 (B-1), Egr-1 and p53 (DO-1) were from Santa Cruz Biotechnology. Mouse
specific p53 antibody (mAb, 1C12), cleaved caspase-3 (D175), phospho-Akt (S473), and phospho-Mdm2 (S166) antibodies were from Cell Signaling
Technology. Mdm2 antibody (Ab3) was purchased from Calbiochem, and β-actin
antibody from Sigma.
Reverse transcriptase-Polymerase Chain Reaction (RT-PCR) analysis
Total RNA was extracted from lung tissues harvested from Par-4+/+ and Par-4-/mice and preserved in RNAlater solution (Qiagen) RNeasy Plus Mini kit (Qiagen).
Reverse transcription was performed to synthesize cDNA with random hexamers
using SuperScript III First-Strand Synthesis System (Invitrogen), followed by
PCR. PCR products were then subjected to agarose gel electrophoresis. The
primers used for p53 and 18S are listed below.
Mouse p53 RNA
Forward primer: 5’- tat gtg cac gta ctc tcc tc -3’
Reverse primer: 5’- tgc tgt gac ttc ttg tag atg -3’
18S RNA
Forward primer: 5’- gta acc cgt tga acc cca tt -3’
Reverse primer: 5’- cca tcc aat cgg tag tag cg -3’
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Luciferase assay
Cells were co-transfected with the PG-13 wild-type p53-luc or empty pGL3-luc
reporter plasmid together with β-galactosidase for normalization. 24 hours after
transfection, cells were washed, lysed, and the cell extracts were mixed with
luciferase substrate Steadylite plus from PerkinElmer. Luminescence was
assayed using TopCount plate reader.
Apoptosis assays
Apoptotic nuclei were identified by immunocytochemical (ICC) analysis for active
caspase-3, and/or by 4, 6-diamidino-2-phenylindole (DAPI) staining. A total of
three independent experiments were performed; and approximately 500 cells
were scored in each experiment for apoptosis under a fluorescent microscope.
Statistical Analysis
All experiments were performed in triplicate to verify reproducibility. Two-way
ANOVA (with appropriate post-hoc test) and Student’s t-test were used to
calculate p-values.
RESULTS
Par-4 is necessary for apoptosis induction by 5-FU and IR
In order to assess the cellular role of Par-4 in apoptosis, we used genetically
matched Par-4+/+ or Par-4-/- mouse embryonic fibroblasts (MEFs) and
investigated their response to genotoxic stresses exerted by treatment with 5Fluorouracil (5-FU) or Ionizing Radiation (IR). We noted that, after 24 hours of
treatment, Par-4+/+ MEFs underwent a gradual dose-dependent increase in
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apoptosis with 5-FU and IR treatment, whereas Par-4-/- MEFs remained
significantly resistant to these agents (Fig. 3.1A and 3.1B).
Par-4 is required for stress-induced p53 stabilization, transcriptional
activity, and apoptosis
It is widely known that wild-type p53 undergoes rapid activation and stabilization
in response to treatment with 5-FU and IR, and induces p53-dependent
apoptosis in the event of intractable cellular damage (Bunz et al., 1999; Lowe et
al., 1993a; Mirzayans et al., 2013). Since both Par-4+/+ and Par-4-/- MEFs
possess wild-type p53, treatment with 5-FU and IR was therefore expected to
elicit a normal p53 stabilization response in both the MEFs. Hence, we decided
to probe for p53 accumulation in response to these treatments in the wild-type
and Par-4-null MEFs. Par-4+/+ MEFs, as expected, exhibited p53 accumulation
when treated with 5-FU (10μM) or IR in a time- and dose-dependent manner.
However, we were most intrigued to notice little or no induction of p53 protein
expression in Par-4-/- MEFs after such treatments (Fig. 3.2A and 3.2B). In order
to determine that Par-4-null cells were not inherently defective in regulating the
expression of stress-inducible genes, we tested for the expression of Early
growth response-1 gene product (Egr-1) in 5-FU treated samples. Our results
showed a steady increase in Egr-1 protein expression 30 minutes after 5-FU
treatment in both Par-4+/+ and Par-4-/- MEFs. In addition, we observed similar
temporal sequence of Egr-1 induction and degradation in both Par-4+/+ and Par-4/-

cells. Interestingly, p53, which is known to be transcriptionally regulated by Egr-

1, was not appreciably induced in Par-4-/- cells in spite of robust Egr-1 induction
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(Fig. 3.2A). Next, we assessed p53 function in both the MEFs using PG13-luc, a
luciferase reporter construct containing 13 copies of the wild-type p53-binding
consensus sequence. When we co-transfected the PG13-luc construct along with
β-galactosidase (for normalization), our results indicated that lower expression of
p53 protein in Par-4-/- cells also translated to a corresponding reduction in p53
transcriptional activity (Fig 3.2C).
These results implied that Par-4-/- MEFs were resistant to 5-FU- or IR-induced
apoptosis because of impaired p53 activation/stabilization and function. We
sought to investigate if the apoptosis resistance exhibited by Par-4-/- MEFs could
entirely be ascribed to attenuated p53 expression. For this purpose, Par-4-/MEFs were infected with either GFP (control), or GFP-p53, or GFP-Par-4
adenovirus constructs, and after confirming the expression of these constructs,
these cells were treated with either vehicle control, or with different doses of 5FU for 24 hours, after which they were analyzed for apoptosis. As seen in Fig.
3.2D, re-introducing Par-4 into Par-4-null system restored the apoptotic potential
of 5-FU in these cells. Replenishing p53 levels in these cells showed an increase
in apoptosis; however, this effect did not match the extent of apoptosis produced
by Par-4 over-expression, and thus represented only a partial recovery of 5-FUinduced apoptosis. Therefore, Par-4-induced apoptosis in response to 5-FU
appears to be only partially mediated by p53, and also involves p53-independent
pathways.
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Par-4 is required for p53 protein stability under basal conditions
Based on our observation that p53 stabilization in response to genotoxic stresses
was so severely compromised in the absence of Par-4, we decided to assess if
there was any difference in basal expression of p53 in various tissues harvested
from Par-4+/+ and Par-4-/- animals, as well as in MEFs derived from these
animals. As is evident in Fig. 3.3A, Par-4-/- tissues and MEFs showed markedly
reduced expression of p53 in comparison to their Par-4+/+ counterparts; the
difference being more pronounced in tissues than in MEFs. Next, we sought to
verify that our results reflected a direct role of Par-4 in p53 stability. We reintroduced Par-4 into Par-4-null MEFs by adenoviral infection, and assessed p53
expression 24 hours post infection. Interestingly, with increasing dosage of Par-4
re-expression in Par-4-/- cells, p53 expression also showed gradual stabilization
(Fig. 3.3B).
Moreover, we wanted to ascertain that our observation was not limited to Par-4
knock-out animals and MEFs produced from them, but was a global effect of Par4 loss. To test this, Par-4 expression was knocked-down in A549 and HOP92
lung cancer cells by transfection of lentiviral shRNA particles, and the cells stably
expressing the shRNA were selected with the help of Puromycin. Knock-down of
Par-4 expression in A549 cells, which possess wild-type p53, resulted in lowering
of p53 expression, similar to our results in Par-4-/-

background; whereas in

HOP92 cells, which possess mutant p53, Par-4 knock-down had no effect (Fig.
3.3C). We could draw two major inferences from this result: a) Par-4 does not
regulate the p53 promoter, because if it did, Par-4 knock-down should have
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resulted in reduced expression of mutant p53 in HOP92 cells also. b) Par-4 is
required for p53 protein stability. As a confirmatory step, we performed reverse
transcription-polymerase chain reaction (RT-PCR) on RNA derived from lungs of
Par-4+/+ and Par-4-/- mice, and as depicted in Fig. 3.3D, p53 mRNA in these
samples did not exhibit any difference in expression. These experiments clearly
implicated a role for Par-4 in p53 stabilization, and hence we decided to
investigate p53 protein stability in cells with or without Par-4.
Par-4 loss results in elevated Mdm2 activity and reduced p53 stability
We examined p53 protein expression in isogenic pairs of cell lines differing only
in their expression of Par-4 (with Par-4 levels either intact, or entirely absent or
knocked down) after treatment with Cycloheximide (CHX) (10μg/ml). CHX inhibits
de novo protein synthesis, and hence would help us study the kinetics of p53
degradation, and therefore, its overall stability, in the presence or absence of
Par-4. In Par-4-null MEFs, and in A549 cells in which Par-4 is knocked-down
(A549 Par-4 sh), stability of p53 protein appeared to be significantly reduced in
comparison to Par-4+/+ MEFs (Fig. 3.4A) and to A549 cells with normal levels of
Par-4 (A549 Con sh) (Fig. 3.4B), respectively. Moreover, as expected, the same
treatment of HOP92 cells revealed highly stable form of mutant p53, high
expression of which was maintained irrespective of CHX treatments or Par-4
status (Fig. 3.4C).
On the basis of these results, we hypothesized that p53 faced an accelerated
rate of degradation, and therefore displayed less stability in the absence of Par-4,
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which led us to evaluate Mdm2-mediated p53 degradation in the presence and
absence of Par-4. Mdm2, an E3 ubiquitin ligase, is the best characterized
negative regulator of p53 stability. We sought to investigate if changes in the
expression and/or activity of Mdm2 could account for decreased stability of p53
in Par-4-null situation. To this end, we used Nutlin-3a to inhibit Mdm2-p53
interaction (Vassilev et al., 2004) in both Par-4+/+ and Par-4-/- MEFs, the rationale
being p53 expression should rise to comparable levels in both the MEFs if Mdm2
was involved. We treated these MEFs for 24 hours with Nutlin-3a, and further
incubated them in the presence of 10μg/ml CHX, or vehicle control, after which
cell lysates were harvested at different time points and analyzed by western blot.
As seen in Fig. (3.4D), treatment with Nutlin-3a significantly stabilized p53
expression in both Par-4+/+ and Par-4-/- MEFs, and the discrepancy in p53 levels
that was observed without Mdm2 inhibition was lost. This result clearly pointed
towards elevated Mdm2-mediated degradation of p53 due to Par-4 loss.
Several groups have reported that the cell survival kinase Akt negatively
regulates p53 expression and function by phosphorylating Mdm2 at Serine-166
(S166) and Serine-186 (S186) - an event that not only enhances Mdm2 ubiquitin
ligase activity, but also promotes its translocation into the nucleus, where it
induces rapid ubiquitination, subsequent nuclear export and proteasomal
degradation of p53, thus effectively inhibiting p53 function (Gottlieb et al., 2002;
Mayo and Donner, 2001; Ogawara et al., 2002; Schmitz et al., 2006; Zhou et al.,
2001). Previous research has revealed that loss of Par-4 results in elevation of
Akt activity (Joshi et al., 2008). Therefore, we next performed serum stimulation
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experiment with Par-4+/+ and Par-4-/- in order to evaluate the levels and activity of
Akt as well as Mdm2 in these cells. When Par-4+/+ and Par-4-/- MEFs were made
quiescent with serum-free media for four hours, and then stimulated by addition
of serum, we found that Akt was activated to a greater degree in Par-4-/- cells
than in Par-4+/+ [reflected by increased Akt phosphorylation at Serine 473
(S473)]. Even more remarkable was the increase in levels of phospho-Mdm2
(S166) in Par-4-/- cells (Fig. 3.4E). Re-stimulation with serum elicits a cell survival
program wherein activated Akt rapidly phosphorylates Mdm2 at Serine-166 and
at

Serine-186;

these

phosphorylation

events

augment

Mdm2-mediated

ubiquitination and degradation of p53. Our results suggest that the absence of
Par-4 and consequent elevation of Akt activity promotes the activation of AktMdm2-p53 axis, which leads to reduced expression and attenuated function of
p53. These results were further validated using cells expressing constitutively
active form of Akt. When compared to wild-type cells, cells with constitutively
active Akt displayed, as expected, increased Akt phosphorylation at S473; very
low levels of Par-4; enhanced Mdm2 (S166) phosphorylation; and significantly
diminished expression of p53 (Figure 3.4F), which corroborates our findings with
Par-4-null MEFs.
DISCUSSION
In this study, we have identified a novel role for the tumor suppressor Par-4 in
regulating the expression and function of another tumor suppressor- p53. P53, a
stress-induced transcription factor, constitutes a hub of signaling networks
controlling critical cellular and organismal phenotypes. Many therapeutic agents
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and genotoxic stresses exert their apoptotic effect by activating and stabilizing
p53, which then sets into motion complex cellular machineries to orchestrate
apoptotic cell death. Consequently, p53 loss or mutation, which occurs in more
than half of human cancers, is known to confer resistance to apoptosis by
various radio- and chemo-therapeutic agents, namely, UV, IR, 5-FU, Adriamycin,
Etoposide, Vincristine etc (Lowe et al., 1993a). Interestingly, Par-4 loss or downregulation is also deemed to confer chemo- or radio-resistance, as documented
by a number of research studies conducted on cell culture systems, mouse
models, as well as tumor specimens. This study, performed on MEFs obtained
from either wild-type or Par-4 knock-out mice, also demonstrates that lack of Par4 results in increased resistance to apoptosis by 5-FU and IR (both of which are
known to activate p53) in spite of the presence of wild-type p53 in both cell types.
Alvarez et al., 2013, have also observed that breast cancer cells in which Par-4
expression is down-regulated are resistant to apoptosis by p53-activating agents
such as Adriamycin despite possessing wild-type p53. It is thus interesting to
note how the presence of wild-type p53 appears to be ineffectual in causing
apoptosis when Par-4 expression is lost or down-regulated. Our study hereby
presents evidence that p53 expression and function is severely compromised by
loss of Par-4; and therefore serves to shed light on the potential mechanism of
therapy resistance engendered by Par-4 loss or down-regulation.
Our results show that p53 expression is reduced in Par-4-/- mice; in MEFs
produced from Par-4-/- mice; as well as in A549 cells in which Par-4 expression
level has been knocked-down, as compared to their Par-4+/+ counterparts, which
93

indicates a definite role for Par-4 in regulating p53 expression. Furthermore,
restoration of p53 expression in Par-4-/- cells with Par-4 re-introduction
unequivocally corroborates this finding. The tight regulation of p53 protein level
within cells is achieved not so much by changes in p53 transcription, but primarily
by modulating Mdm2-mediated p53 degradation (Kruse and Gu, 2009; Oren,
1999). Indeed, several lines of evidence in our study indicate that regulation of
p53 by Par-4 is at the level protein stabilization, as outlined below.
 Our RT-PCR data failed to reveal significant differences in p53 mRNA
expression.
 Par-4 knock-down failed to impact p53 levels in HOP92 lung cancer cell
line, which carries an arginine to leucine mutation at position 175 (175
R/L), and is known to possess relatively elevated basal levels of the
mutant protein (O'Connor et al., 1997). Conversely, wild-type p53 levels in
A549 lung cancer cells were effectively reduced by knock-down of Par- 4
expression. This result rules out the possibility of Par-4 regulating p53
promoter, because, if this effect were promoter-driven, expression levels
of both the mutant and wild-type forms of p53 should have been impacted.
 In addition, our cycloheximide experiments clearly indicate that, when de
novo protein translation is inhibited, Par-4 loss or down-regulation results
in a significant drop in wild-type p53 protein stability, thereby suggesting
the presence of a hyper-active p53 degradation mechanism in cells that
lack Par-4.
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Mdm2, an E3 ubiquitin ligase with a high specificity for p53, is the best
characterized negative regulator of p53 expression and function. Mdm2
directly binds to p53, and tightly controls its basal levels via continuous
ubiquitination and consequent degradation by the 26S proteasome (Haupt et
al., 1997; Honda et al., 1997; Kubbutat et al., 1997). Mdm2-mediated
ubiquitination also promotes nuclear export of p53; and this exit from the
nucleus and cytoplasmic relocation is essential for its proteasomal
degradation (Boyd et al., 2000; Geyer et al., 2000). In addition, Mdm2
complexed with p53 is known to localize to regulatory regions of a number of
p53 target genes and repress their transcriptional activation (Manfredi, 2010;
Momand et al., 1992). Upon exposure to genotoxic or other cellular stresses,
interaction between Mdm2 and p53 is disrupted, which alleviates p53 from
Mdm2-mediated repression, leading to p53 stabilization and transactivation of
specific p53 target genes (Manfredi, 2010). The small molecule Mdm2
antagonist Nutlin-3a, which binds to the p53-binding pocket in Mdm2 and thus
disrupts Mdm2-p53 interaction, is shown to be sufficient to cause p53
accumulation and transcriptional activation of p53 target genes (Vassilev et
al., 2004). Our experiment with Par-4-/- cells treated with Nutlin-3a and CHX,
and the stabilization of p53 observed thereof, distinctly implicates Mdm2mediated p53 degradation as a plausible cause for p53 protein instability in
Par-4-null cells.
Excessive Mdm2-mediated degradation of p53 could reflect either augmented
expression, or elevated activity of Mdm2 protein, or both. Myriad of post95

translational modifications on both p53 and Mdm2 have been described to
influence the interaction between the two. Phosphorylation of Mdm2 by
Akt/PKB serine/threonine kinase at two consensus sites- S166 and S186- is
known to: a) enhance its E3 ubiquitin ligase activity; b) facilitate its
translocation from the cytoplasm to the nucleus; c) lead to nuclear export of
p53 and subsequent proteasomal degradation; and d) afford protection
against p53-mediated apoptosis induced by genotoxic agents across a
number of cellular and tumor paradigms (Gottlieb et al., 2002; Limesand et
al., 2006; Mayo and Donner, 2001; Ogawara et al., 2002; Zhou et al., 2001).
In this light, it is interesting to note that Par-4 has been shown to inhibit Akt
activity (Joshi et al., 2008), and our serum re-stimulation results also indicate
elevated Akt activity, as well as augmented levels of phospho-Mdm2 (S166),
which invariably translates to lower p53 levels, in Par-4-/- cells in comparison
to that in Par-4+/+ cells. Taken collectively, our results suggest that loss of
Par-4-mediated Akt inhibition, and consequent elevation in Mdm2 activity, is
responsible for decreased p53 expression and transcriptional activity;
impaired p53 stabilization in response to genotoxic stresses, such as
treatment with 5-FU and IR; and increased threshold for apoptosis induction
in response to 5-FU and IR observed in Par-4-null cells. This work, therefore,
provides a novel mechanistic insight into how Par-4 loss or down-regulation
could be associated with therapy resistance in tumors possessing wild-type
p53.
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Fig. 3.1: Par-4-null cells are resistant to apoptosis by 5-FU or IR
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Figure 3.1: Par-4-null cells are resistant to apoptosis by 5-FU or IR
(A) Par-4-null MEFs demonstrate increased resistance to 5-FU treatment.
Par-4+/+ and Par-4-/- MEFs were treated with indicated doses of 5-FU for
24 hours, and the cells were scored for apoptosis by ICC for DAPI and
active caspase-3 staining.
(B) Par-4-null MEFs demonstrate increased resistance to IR. Par-4+/+ and
Par-4-/- MEFs were exposed to 2, 4 or 6 Grays (Gy) of radiation for 24
hours, and apoptosis was assayed by ICC for DAPI and active caspase-3.
(A, B) Asterisk (**) indicates statistical significance (P < 0.001) based on two-way
ANOVA followed by Bonferroni correction.
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Fig. 3.2: Stress-inducible p53 stabilization and function is compromised in
Par-4 loss
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Fig. 3.2: Stress-inducible p53 stabilization and function is compromised in
Par-4 loss
(A) Par-4 is required for p53 accumulation after 5-FU treatment. Par-4+/+
and Par-4-/- MEFs were treated with either 10μM 5-FU or with vehicle
control, DMSO. Cell lysates were harvested at the indicated time points
and analyzed for p53 and Egr-1 expression by western blotting. Actin is
used as loading control.
(B) Par-4 is required for p53 accumulation after exposure to IR. Par-4+/+
and Par-4-/- MEFs were treated with 2, 4, and 6 Gy radiation, and the
lysates were harvested 30 minutes or 90 minutes after exposure to IR.
The whole cell lysates were subjected to western blotting and analyzed for
p53 expression. Actin is used as loading control.
(C) P53 transcriptional activity is attenuated in Par-4-null situation. Par4+/+ and Par-4-/- MEFs were transfected with either empty luciferase
construct (pGL3-luc) or with a luciferase construct driven by p53 response
elements (p53-luc). 24 hours later, cell extracts were assayed for
luciferase activity, which is expressed as fold induction over basal activity
produced by empty luc vector pGL3-luc.
(D) P53 replenishment in Par-4-null cells partially rescues the apoptotic
potential of 5-FU. Par-4-/- MEFs were infected with adenoviral constructs
expressing either GFP, or GFP-p53 or GFP-Par-4 proteins. 18 hours after
infection, cells were treated with the indicated doses of 5-FU for 24 hours,
and assayed for apoptosis by DAPI positivity of pyknotic nuclei.
(C, D) Asterisk (**) indicates statistical significance (P < 0.001) based on two-way
ANOVA.
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Fig. 3.3: Par-4 is required for p53 protein stability under basal conditions
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Fig. 3.3: Par-4 is required for p53 protein stability under basal conditions
(A) Basal expression of p53 is reduced in Par-4-null situation. Par-4+/+
and Par-4-/- cell lysates, as well as protein extracts prepared from the
indicated organs harvested from Par-4+/+ and Par-4-/- mice were subjected
to western blotting and probed for p53, Par-4 and actin.
(B) Par-4 induces p53 protein stability. Par-4-/- MEFs were transduced with
Par-4 expressing adenoviral construct. Cell lysates were collected 24
hours after infection and analyzed by western blotting.
(C) Par-4 is required for stability of wild-type, but not mutant, p53. A549
and HOP92 lung cancer cells were infected with lentiviral particles
containing either control shRNA (Con sh) or Par-4 shRNA (Par-4 sh) in
order to silence Par-4 expression. Cells stably expressing the desired
shRNA were selected by Puromycin treatment, and the lysates were
analyzed for the expression of p53 by western blotting. A549 and HOP92
cells stably expressing either Control or Par-4 shRNA were prepared by
Dr. Sunil Nooti.
(D) Par-4 does not regulate p53 RNA levels. Total RNA was extracted from
lungs harvested Par-4+/+ and Par-4-/- mice, and subjected to reverse
transcriptase PCR (RT-PCR) for analysis of p53 mRNA levels. 18S RNA
is used as control.
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Fig. 3.4: Par-4 loss results in elevated Mdm2 activity
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Fig. 3.4: Par-4 loss results in elevated Mdm2 activity
(A) p53 protein stability is reduced in the absence of Par-4 in primary
MEFs. Par-4+/+ and Par-4-/- MEFs were treated with Cycloheximide (CHX),
inhibitor of de novo protein synthesis, at the concentration of 10μg/ml. Cell
lysates were harvested at the indicated time points and analyzed by
western blot for the indicated proteins.
(B) P53 protein stability is reduced in the absence of Par-4 in lung
cancer cells. A549 cells (possessing wild-type p53) expressing either
control shRNA or shRNA for Par-4 were treated with 10μg/ml
Cycloheximide or vehicle control; cell lysates were harvested at indicated
time points and subjected to western blot to analyze p53 protein.
(C) Par-4 does not affect stability of mutant p53. HOP92 cells (possessing
mutant p53) expressing either control shRNA or shRNA for Par-4 were
treated with 10μg/ml Cycloheximide or vehicle control; cell lysates were
harvested at indicated time points and subjected to western blot to
analyze p53 protein.
(D) P53 stability caused by Par-4 loss is rescued by Mdm2 inhibition.
Par-4+/+ and Par-4-/- MEFs were pre-treated for 24 hours, and then treated
with CHX for the indicated time points. Cell lysates were analyzed by
western blotting.
(E) Par-4 inhibits Akt-mediated phosphorylation of Mdm2 at S166. Par4+/+ and Par-4-/- MEFs were serum starved for 4 hours, and re-stimulated
with 10% serum for short time periods in order to activate Akt. Cell lysates
were collected at the indicated time points, and analyzed for the indicated
proteins and phospho-proteins by western blotting.
(F) Akt activity induces Mdm2 (S166) phosphorylation. Wild-type (WT)
cells and cells expressing constitutively active form of Akt were lysed,
harvested, and the lysates were subjected to western blotting and probed
for the indicated proteins. Performed by Nikhil Hebbar.
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CHAPTER FOUR: DISCUSSION AND FUTURE DIRECTIONS
Selectivity towards cancer cells is perhaps the most desirable, and yet, the most
elusive trait sought after in cancer therapy. The tumor suppressor Par-4, because
of its unique cancer cell-specific apoptotic action, presents considerable
therapeutic promise. In addition, Par-4 is secreted, and can act both
intracellularly (both in the cytoplasm and the nucleus) and extracellularly to
induce apoptosis specifically in cancer cells. The tumor suppressor p53, rightfully
titled “the guardian of the genome”, holds the reins to a broad range of effector
functions that contribute to its tumor suppressive effects. P53 transcriptionally
controls and co-ordinates critical processes like cell cycle arrest, cellular
senescence and apoptosis; and its emerging role in other important processes
like autophagy and cellular metabolism is being increasingly chronicled. This
dissertation work describes a fascinating cross-talk between these two tumor
suppressors wherein they mutually regulate different facets of each other’s
functions. Par-4, which is secreted in response to p53 activation, executes the
paracrine apoptotic effect of p53 in a cancer cell-selective manner (chapter 2).
Par-4, on the other hand, plays a role in p53 stabilization; and this mechanism
probably serves to explain the apoptosis resistance conferred by par-4 loss to
genotoxic insults that normally induce p53-dependent apoptosis (chapter 3).
Reciprocal interactions between the tumor and its microenvironment, and the role
of a supportive, reactive stroma in the development, progression and metastasis
of tumors have been well documented. Lately, many studies have reported that
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wild-type p53 in the stroma inhibits tumor growth, and that tumor progression
selects for inactivation of p53 in the stromal compartment, particularly in cancer
associated fibroblasts (CAFs) (Hill et al., 2005; Kiaris et al., 2005; Kurose et al.,
2002). Most of these studies, however, have been largely descriptive, and the
mechanism whereby wild-type p53 in the fibroblasts could exert inhibitory effect
on tumor growth is yet to be addressed.
Our findings in chapter 2 reveal that Par-4, a tumor suppressor with potent
apoptotic activity towards cancer cells, is secreted in response to p53 activation,
and mediates the paracrine tumor suppressive effects of p53 (Figure 4.1). Since
p53 function is frequently compromised in human cancers due to deletion or
mutation of Tp53 gene, it is obvious that p53 protein in such scenarios will not be
amenable to activation by Mdm2 inhibitor Nutlin-3a and NF-κB inhibitor PS1145.
Therefore, we circumvented that problem by empowering the normal cells
(normal fibroblasts which possess wild-type p53) to induce Par-4 secretion. Our
experiments with mice indicate that a single injection of Nutlin-3a+PS1145 builds
up adequate Par-4 in the serum to cause ex vivo apoptosis of cancer cells. Like
p53, other molecular regulators of Par-4 secretion can be identified, and then
pharmacologically targeted to induce Par-4 secretion from normal cells. In fact, a
recent publication identified one such target, vimentin, which can be inhibited by
Arylquin 1, to enhance Par-4 secretion (Burikhanov et al., 2014b). Therefore,
identification of such molecular targets opens up avenues for rational drug design
and development of Par-4 ‘secretagogues’ which promise immense therapeutic
potential.
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Our results suggest that Par-4 secretion in response to Nutlin-3a+PS1145 is
induced by p53-mediated repression of UACA, a binding partner of Par-4.
Binding of Par-4 by UACA results in Par-4 sequestration; and inhibition of UACA
expression either by p53-mediated transcriptional repression or by NF-κB
inhibition can have two consequences:
a) In cancer cells: Liberation of Par-4 from sequestration by UACA, and an
increase in the expression of Par-4 receptor GRP78 on the surface of
cancer cells, rendering them more sensitive to extracellular Par-4mediated apoptosis (Burikhanov et al., 2013).
b) In cells with intact p53 pathway: Liberation of Par-4 from sequestration by
UACA, and an increase in Par-4 secretion.
Our results with NF-κB inhibitors showing UACA down-regulation and enhanced
Par-4 secretion from normal wild-type fibroblasts may have wider implications.
Interestingly, UACA was identified as a protein up-regulated in inflammatory
disease (panuveitis) (Yamada et al., 2001), and is positively regulated by NF-κB
activity (Tran et al., 2010). By logical extension, then, we can hypothesize that
drugs with anti-inflammatory properties (for example, NSAIDs) will be able to
induce Par-4 secretion. Although NSAIDs are known to inhibit the enzymes
cyclooxygenase-1 and/or -2 (COX-1, COX-2), some NSAIDs such as Aspirin,
Sodium salicylate, Sulfasalazine, Sulindac (Yamamoto and Gaynor, 2001), and
Ibuprofen (Greenspan et al., 2011) also inhibit NF-κB-mediated transcriptional
activation.
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Meta analyses of epidemiological data collected from different patient cohorts
have discussed potential chemo-preventive effects associated with NSAID use
against tumors at various sites, including prostate, breast, lung, brain, and
melanoma (Liu et al., 2014a). In addition, these agents are also known to induce
regression of adenomatous polyps of the colon and prevent development of
colon cancer (Yamamoto and Gaynor, 2001). It will be interesting to examine if
NF-κB inhibition by NSAIDs will result in elevated Par-4 secretion, and better still,
to investigate if the chemo-preventive potential demonstrated by the use of these
NSAIDs can be associated with the increase in Par-4 secretion. Data from Par4/SAC transgenic mice indicate an increased resistance to cancer with elevated
serum levels of Par-4 protein. Considering cancer cell-specific apoptotic nature
and tumor suppressive function of Par-4, it is possible that there is a correlation
between secreted Par-4 and cancer risk, which may constitute an important
aspect in Par-4 research.
A particularly intriguing aspect of cross-talk between Par-4 and p53 is regulation
of p53 stabilization by Par-4 (chapter 3). Using Par-4 wild-type and Par-4-null
MEFs, we show that Par-4-null cells are significantly resistant to apoptosis by
genotoxic agents such as IR and 5-FU, in spite of the fact that both sets of MEFs
possess wild-type p53. It is well established that treatment with IR or 5-FU results
in p53 stabilization/accumulation, and ultimately leads to p53-dependent
apoptosis (Lowe et al., 1993a; Lowe et al., 1993b; Mirzayans et al., 2013). Even
though apoptosis resistance conferred by Par-4 loss or down-regulation has
been well studied, we show for the first time that p53 stress response is severely
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attenuated in the absence of Par-4. Our results indicate that Par-4 loss leads to
elevated Mdm2 activity, as judged by remarkable increase in Mdm2 (S166)
phosphorylation, thereby resulting in reduced p53 stability (Figure 4.2). These
results might have implications in therapy resistance shown by some cancers
bearing wild-type p53.
Renal cell carcinoma (RCC) is one of the few types of cancers that retain wildtype p53. In fact, existing data suggests that approximately 86% of RCC contain
wild-type p53. However, RCC is also characterized by increased co-expression
of Mdm2; and such co-expression pattern is linked with poor disease prognosis
(Polanski et al., 2014). Despite majority of RCC cases possessing wild-type p53,
this disease exhibits exceptionally high resistance to radiation and chemotherapy
(Cook et al., 1999). It is interesting to note that over 70% of human RCC show
significant down-regulation of Par-4. Furthermore, replenishment of Par-4 protein
into RCC cell lines established from two different RCC tumors restored
therapeutic sensitivity of these cells to the apoptotic effects of Adriamycin and
TNF- α (Cook et al., 1999). This result definitely indicates that apoptotic response
of RCC cell lines is regained with Par-4 restoration. On the other hand, p53
stabilization using Mdm2 inhibitor Nutlin-3 is reported to induce growth arrest and
senescence in RCC cells (Polanski et al., 2014). Was p53 activation/stabilization
in response to Adriamycin compromised in RCC cells containing low Par-4?
Does Par-4 down-regulation in RCC correlate with therapy resistance and poor
disease outcome? Do Par-4 down-regulation and Mdm2 over-expression show
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an inverse correlation? These not only constitute interesting research questions
for the future, but might influence the choice of therapy used for RCC.
Dudley et. al. reported a similar phenomenon of impaired p53 function in tumorassociated stromal cells from A375 melanoma and PC3 prostate carcinoma
xenografts and a spontaneous prostate tumor model TRAMP. They found that,
upon treatment with p53-activating agents such as Etoposide and Vincristine,
these tumor-associated stromal cells failed to accumulate p53, and showed
increased resistance to growth inhibitory and apoptotic effects of these drugs,
despite the fact that p53 sequence remained wild-type. Such lack of response
demonstrated by tumor-associated stromal cells is reminiscent of that shown by
Par-4-null fibroblasts. Therefore, it may be worthwhile investigating if Par-4 status
is altered in cancer-associated stroma during tumor progression, and examining
whether such alteration, if present, has a bearing on how the stroma responds to
therapy.
It is known that the kind of effector function elicited by p53 is highly context
dependent (Zilfou and Lowe, 2009). We now know that loss of Par-4
compromises p53 pathway and renders cells more resistant to apoptosis.
However, whether other p53-regulated processes, such as cell cycle arrest,
senescence, autophagy, and cellular metabolism also get similarly affected by
Par-4 loss remains to be investigated. In addition, is reduced stability of p53 in
the absence of Par-4 solely due to Akt-mediated activation of Mdm2? It is also
likely that Par-4 can directly bind and modulate Mdm2 activity, given our

114

observation of such strong inhibition of p53 expression due to Par-4 loss. Direct
regulation of Mdm2 expression/activity by Par-4 also needs to be examined.
In summary, the studies described in this dissertation elaborate how the mutual
interplay between the two tumor suppressors p53 and Par-4 has helped:
 Conceptualize a novel strategy of empowering normal cells to combat
remote cancer cells by releasing a cancer cell-specific killer protein.
 Elucidate the mechanism by which Par-4 loss may confer therapy
resistance in cells that possess wild-type p53.
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Figure 4.1: Par-4 mediates the paracrine apoptotic effect of p53

Fig 4.1: Par-4 mediates the paracrine apoptotic effect of p53. P53 activation
by Nutlin-3a and NF-κB inhibition by PS-1145 results in robust p53 activation,
thereby leading to synergistic increase in Par-4 secretion. Extracellular Par-4
then targets cancer cells in remote locations, thus executing the paracrine
apoptotic effect of p53 in a cancer cell-specific manner.
Adapted and modified from Burikhanov et. al., Cell Rep. 2014 Jan 30;6(2):271-7.
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Figure 4.2: Par-4 regulates p53 stability

Figure 4.2: Par-4 regulates p53 stability. The E3 ligase activity is enhanced by
Akt, which in turn is inhibited by Par-4. In the absence of Par-4, Akt-mediated
phosphorylation of Mdm2 at S166 activates it, and results in an increased rate of
p53 degradation, as well as inhibition of p53 transcriptional activity.
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